[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 63 of about 63
1. Bai Y, Zhou G, Nakamura M, Ozaki T, Mori I, Taniguchi E, Miyauchi A, Ito Y, Kakudo K: Survival impact of psammoma body, stromal calcification, and bone formation in papillary thyroid carcinoma. Mod Pathol; 2009 Jul;22(7):887-94
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival impact of psammoma body, stromal calcification, and bone formation in papillary thyroid carcinoma.
  • The presence of calcification is the most significant ultrasonographic finding in evaluating thyroid nodules.
  • Calcifications are more frequently detected in papillary thyroid carcinoma than in other thyroid lesions.
  • However, the clinical significance of calcification, including clinical correlations and impact on survival, and the molecular mechanism responsible for calcification in papillary thyroid carcinoma remain uncertain.
  • We performed a retrospective study of patients with primary common-type papillary thyroid carcinoma to determine the clinical correlations of calcification and its impact on survival.
  • They were identified in 25, 47, and 13% of all 229 cases of papillary thyroid carcinoma, respectively.
  • The presence of psammoma bodies was significantly correlated with gross lymph node metastasis and stage grouping.
  • Papillary thyroid carcinoma with, compared to that without, psammoma bodies was associated with poorer disease-free survival.
  • These results suggest that the presence of psammoma bodies is a useful predictor of outcome for patients suffering from papillary thyroid carcinoma.
  • [MeSH-major] Adenocarcinoma, Papillary / mortality. Calcinosis / mortality. Thyroid Neoplasms / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19305382.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.24.19 / BMP1 protein, human; EC 3.4.24.19 / Bone Morphogenetic Protein 1
  •  go-up   go-down


2. Griniatsos J, Tsigris C, Kanakis M, Kaltsas G, Michail O, Dimitriou N, Argyrakopoulou G, Delladetsima I, Kyriakou V, Syriou V, Alexandraki K, Pikoulis E, Giannopoulos A, Kouraklis G, Diamanti-Kandaraki E, Felekouras E: Increased incidence of papillary thyroid cancer detection among thyroidectomies in Greece between 1991 and 2006. Anticancer Res; 2009 Dec;29(12):5163-9
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased incidence of papillary thyroid cancer detection among thyroidectomies in Greece between 1991 and 2006.
  • OBJECTIVE: To examine existing evidence, trends and possible factors that may have affected the incidence of papillary thyroid cancer (PTC) among patients undergoing thyroidectomies in an iodine-sufficient population of Greece.
  • STUDY DESIGN: All histology records from the patients who had undergone thyroid surgery at the Department of Surgery Laiko Hospital, Athens, Greece from January 1991 to December 2006 were retrospectively analyzed.
  • Thyroid tumors were classified according to the WHO classification system and were staged according to the TNM staging system.
  • From 1999 onwards, thyroid surgery shifted towards total thyroidectomy, while statistically significantly increased incidence of PTC and papillary microcarcinoma detection and decreased incidence of PTC greater than 10 mm detection in the whole population were noticed.
  • Moreover, from 1999 onwards, smaller size of primary tumors, higher incidence of T1 tumors, lower incidence of T4 tumors, lower incidence of metastatically infiltrated peritracheal lymph nodes, higher incidence of stage I tumors and lower incidence of stage IV tumors were documented.
  • CONCLUSION: The increased incidence of PTC clearly correlated to the increased incidence of papillary microcarcinoma detection, reflecting the proportion for total thyroidectomy as well as changes in the diagnostic approach boosted by more careful pathological examination, rather than the effect of environmental factors such as the Chernobyl accident.
  • [MeSH-major] Adenocarcinoma, Follicular / epidemiology. Adenoma, Oxyphilic / epidemiology. Carcinoma / epidemiology. Carcinoma, Medullary / epidemiology. Carcinoma, Papillary / epidemiology. Thyroid Neoplasms / epidemiology. Thyroidectomy

  • Genetic Alliance. consumer health - Thyroid cancer, papillary.
  • Genetic Alliance. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20044632.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


3. Masago K, Asato R, Fujita S, Hirano S, Tamura Y, Kanda T, Mio T, Katakami N, Mishima M, Ito J: Epidermal growth factor receptor gene mutations in papillary thyroid carcinoma. Int J Cancer; 2009 Jun 1;124(11):2744-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermal growth factor receptor gene mutations in papillary thyroid carcinoma.
  • Recent studies have indicated that somatic mutations in the epidermal growth factor receptor (EGFR) gene have been identified in a subset of patients with nonsmall-cell lung cancer (NSCLC) and are associated with sensitivity to the EGFR-tyrosine-kinase inhibitors.
  • These mutations have been reported to be almost exclusively found in a pulmonary adenocarcinoma subgroup of NSCLC, with a low frequency in other solid tumors.
  • We describe a patient with advanced-stage papillary thyroid carcinoma (PTC) whose disease had been diagnosed as pulmonary adenocarcinoma at first, and who had a marked response to the EGFR-tyrosine-kinase inhibitor, gefitinib.
  • An in-frame deletion in exon 19 that eliminated 4 amino acids at positions 746 through 750, which is one of the common drug-sensitive mutations in pulmonary adenocarcinoma, and a serine-to-proline substitution at codon 752, were found in a tumor specimen of the patient.
  • We subsequently searched for mutations in the EGFR tyrosine kinase domain in primary tumors from 23 patients with PTC, and drug-sensitive mutations commonly observed in pulmonary adenocarcinoma were found in 7 of these patients.
  • Our data suggest that EGFR-tyrosine-kinase inhibitors may deserve consideration in the treatment of a subset of patients with PTC, just as with pulmonary adenocarcinoma.
  • [MeSH-major] Carcinoma, Papillary / genetics. Mutation. Receptor, Epidermal Growth Factor / genetics. Thyroid Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Cancer. 2012 May 1;130(9):2215-7; author reply 2217-8 [21717456.001]
  • (PMID = 19253367.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  •  go-up   go-down


Advertisement
4. Mitsiades CS, Negri J, McMullan C, McMillin DW, Sozopoulos E, Fanourakis G, Voutsinas G, Tseleni-Balafouta S, Poulaki V, Batt D, Mitsiades N: Targeting BRAFV600E in thyroid carcinoma: therapeutic implications. Mol Cancer Ther; 2007 Mar;6(3):1070-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeting BRAFV600E in thyroid carcinoma: therapeutic implications.
  • BRAF mutations have been detected in several tumors, including papillary thyroid carcinoma, but the precise role of B-Raf as a therapeutic target for thyroid carcinoma is still under investigation.
  • We analyzed a panel of 93 specimens and 14 thyroid carcinoma cell lines for the presence of BRAF mutations and activation of the mitogen-activated protein/ERK kinase (MEK)/extracellular signal-regulated kinase (ERK) pathway.
  • We also compared the effect of a B-Raf small inhibitory RNA construct and the B-Raf kinase inhibitor AAL881 on both B-Raf wild-type and mutant thyroid carcinoma cell lines.
  • We found a high prevalence of the T1799A (V600E) mutation in papillary and anaplastic carcinoma specimens and cell lines.
  • There was no difference in patient age, B-Raf expression, Ki67 immunostaining, or clinical stage at presentation between wild-type and BRAF(V600E) specimens.
  • Furthermore, a small inhibitory RNA construct targeting the expression of both wild-type B-Raf and B-Raf(V600E) induced a comparable reduction of viability in both wild-type and BRAF(V600E) mutant cancer cells.
  • We conclude that B-Raf is important for the pathophysiology of thyroid carcinomas irrespective of mutational status.
  • Small molecule inhibitors that selectively target B-Raf(V600E) may provide clinical benefit for patients with thyroid cancer.
  • [MeSH-major] Adenocarcinoma, Follicular / genetics. Carcinoma, Papillary / genetics. Isoquinolines / pharmacology. Mutation / genetics. Proto-Oncogene Proteins B-raf / genetics. Thyroid Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Apoptosis / drug effects. Carcinoma / genetics. Carcinoma / pathology. Carcinoma / prevention & control. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / prevention & control. Cell Proliferation / drug effects. Extracellular Signal-Regulated MAP Kinases / metabolism. Female. Humans. Male. Middle Aged. Mitogen-Activated Protein Kinases / metabolism. Phosphorylation / drug effects. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Signal Transduction / drug effects. Tumor Cells, Cultured / drug effects

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17363500.001).
  • [ISSN] 1535-7163
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AAL 881; 0 / Isoquinolines; 0 / RNA, Messenger; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 2.7.11.24 / Mitogen-Activated Protein Kinases
  •  go-up   go-down


5. Wada N, Masudo K, Nakayama H, Suganuma N, Matsuzu K, Hirakawa S, Rino Y, Masuda M, Imada T: Recommendation for subclass evaluation of TNM stage iva papillary thyroid carcinomas: T4aN1b patients are at risk for recurrence and survival. Ann Surg Oncol; 2008 May;15(5):1511-7
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recommendation for subclass evaluation of TNM stage iva papillary thyroid carcinomas: T4aN1b patients are at risk for recurrence and survival.
  • BACKGROUND: Although all tumor, node, metastasis system (TNM) stage IVA papillary thyroid carcinomas (PTCs) do not seem to behave equivalently as a result of various tumor and node stages, to our knowledge, subclass evaluation has never been attempted.
  • METHODS: We reviewed 119 stage IVA PTC patients who underwent initial thyroidectomy with modified neck dissection as curative surgery at our institution (33 male patients, 86 female patients; age 61.6 years; follow-up 87.7 months).
  • In multivariate analysis, esophageal invasion and lymphadenopathy were independent risk factors for both DFS and DSS in stage IVA PTC patients.
  • CONCLUSIONS: Outcomes in stage IVA are not equivalent, and patients with T4aN1b are at greater risk for worse prognosis.
  • Therefore, we recommend subclass evaluation for TNM stage IVA PTCs.
  • [MeSH-major] Adenocarcinoma, Follicular / secondary. Carcinoma, Papillary / secondary. Neoplasm Recurrence, Local / diagnosis. Thyroid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18299932.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Caresia AP, Castell Conesa J, Obiols Alfonso G, Pifarré Montaner P, Negre Busó M, García Alonso C, Galofré Mora P, Mesa Manteca J: [Comparison of administration of rhTSH with withdrawal of thyroid hormone. Follow-up of patients with differentiated thyroid carcinoma]. Rev Esp Med Nucl; 2006 Jul-Aug;25(4):236-41
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparison of administration of rhTSH with withdrawal of thyroid hormone. Follow-up of patients with differentiated thyroid carcinoma].
  • [Transliterated title] Estudio comparativo entre la utilización de TSH recombinante y la estimulación endógena con TSH. Valoración en el seguimiento de los pacientes con carcinoma diferenciado de tiroides.
  • Recombinant human thyrotropin (rhTSH) has been introduced recently in follow up of differentiated thyroid cancer (DTC) patients, as an alternative of thyroid hormone withdrawal.
  • MATERIAL AND METHODS: Thirty-three patients with DTC with previous thyroidectomy and thyroid ablation were selected.
  • All patients underwent whole-body radioiodine scanning and third day serum thyroglobulin (TG) measurement by two techniques, the first one after conventional thyroid hormone withdrawal (TSHe, TGe), and the second one after rhTSH stimulation (TSHr, TGr).
  • CONCLUSIONS: Administration of rhTSH produces a significantly higher increase of TSH than thyroid hormone withdrawal and lower increase in TG levels.
  • There were no significant differences in the stage of disease (TG and whole-body radioiodine scan).
  • [MeSH-major] Adenocarcinoma, Follicular / radionuclide imaging. Carcinoma, Papillary / radionuclide imaging. Thyroid Neoplasms / radionuclide imaging. Thyrotropin / pharmacology. Thyroxine / administration & dosage

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. LEVOTHYROXINE .
  • Hazardous Substances Data Bank. LIOTHYRONINE .
  • Hazardous Substances Data Bank. THYROGLOBULIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16827986.001).
  • [ISSN] 0212-6982
  • [Journal-full-title] Revista española de medicina nuclear
  • [ISO-abbreviation] Rev Esp Med Nucl
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Iodine Radioisotopes; 0 / Radiopharmaceuticals; 0 / Recombinant Proteins; 0 / anti-thyroglobulin; 06LU7C9H1V / Triiodothyronine; 9002-71-5 / Thyrotropin; 9010-34-8 / Thyroglobulin; Q51BO43MG4 / Thyroxine
  •  go-up   go-down


7. Sampson E, Brierley JD, Le LW, Rotstein L, Tsang RW: Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis. Cancer; 2007 Oct 1;110(7):1451-6
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis.
  • BACKGROUND: Differentiated thyroid cancer has a good prognosis and only rarely presents with distant metastasis at diagnosis.
  • METHODS: A retrospective review was undertaken of patients with stage M1 differentiated thyroid cancer at presentation (n = 49), referred from 1980-2000 at a single institution.
  • HISTOLOGY: papillary, 51%, follicular, 49%.
  • Most deaths (17/24, 71%) were due to progressive cancer.
  • The 3-year survival for lung only versus bone only metastasis was 77% versus 56% (P = .02); for papillary versus follicular carcinoma, 75% versus 62% (P = .006); for iodine-avid disease (n = 29) versus not avid (n = 14), 82% versus 57% (P = .02), respectively.
  • CONCLUSIONS: The data support the aggressive management of patients presenting with stage M1 thyroid cancer, with thyroidectomy and RAI.
  • Young patients with papillary tumors and/or iodine-avid disease have an even better prognosis.
  • [MeSH-major] Adenocarcinoma, Follicular / therapy. Carcinoma, Papillary / therapy. Iodine Radioisotopes / therapeutic use. Thyroid Neoplasms / therapy. Thyroidectomy


8. Silberstein EB: Comparison of outcomes after (123)I versus (131)I pre-ablation imaging before radioiodine ablation in differentiated thyroid carcinoma. J Nucl Med; 2007 Jul;48(7):1043-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of outcomes after (123)I versus (131)I pre-ablation imaging before radioiodine ablation in differentiated thyroid carcinoma.
  • Detection of residual tissue after thyroidectomy for papillary or follicular thyroid carcinoma may be performed using diagnostic imaging with either (123)I or (131)I.
  • This study examines the outcomes of ablative (131)I therapy after diagnostic studies with either (123)I or (131)I to determine if the diagnostic dosages of these radionuclides used in our Thyroid Cancer Center reduce the efficacy of (131)I given for remnant ablation.
  • METHODS: Fifty patients with nonmetastatic papillary or follicular carcinoma of the thyroid received total thyroidectomy; this was followed by thyroid hormone withdrawal to achieve a serum thyroid-stimulating hormone level in excess of 30 microIU/mL.
  • Group 1 had diagnostic imaging with 14.8 MBq of (123)I followed by thyroid remnant ablation with 3.7 GBq of (131)I.
  • Successful ablation required a negative follow-up thyroid scan 6-8 mo after ablation and also an undetectable serum thyroglobulin level in the absence of antithyroglobulin antibodies.
  • RESULTS: There was no significant difference between the 2 groups demographically, in tumor burden or stage, or in the post-thyroidectomy ablation rate (group 1, 81%; group 2, 74%; P > 0.05).
  • CONCLUSION: If thyroid remnant stunning occurs due to 74 MBq (131)I used as a diagnostic agent before (131)I ablation, it has no significant clinical correlate, as it yields the same ablation rate as that which occurs after 14.8 MBq of (123)I used for imaging.
  • [MeSH-major] Adenocarcinoma, Follicular / radionuclide imaging. Carcinoma, Papillary / radionuclide imaging. Iodine Radioisotopes / therapeutic use. Radiopharmaceuticals / therapeutic use. Thyroid Neoplasms / radionuclide imaging
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Thyroid Hormones / blood. Thyroidectomy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Nucl Med. 2008 Jan;49(1):166; author reply 166-7 [18165699.001]
  • (PMID = 17574976.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 0 / Radiopharmaceuticals; 0 / Thyroid Hormones
  •  go-up   go-down


9. Mishunina TM, Kalinichenko OV, Tronko MD, Statsenko OA: Caspase-3 activity in papillary thyroid carcinomas. Exp Oncol; 2010 Dec;32(4):269-72

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Caspase-3 activity in papillary thyroid carcinomas.
  • AIM: The aim of this work was to assess caspase-3 activity in the tissue of papillary thyroid carcinomas of patients and analyze the peculiarities of changes in this activity depending upon a number of pathomorphological and clinical features of tumoral process.
  • RESULTS: At initial stages of tumor development, in the absence of metastases to lymph nodes, blood and lymphatic vessel invasion by tumor cells, extrathyroid spreading of tumor, sclerotic and fibrous changes in tumor stroma, and in the presence of tumor capsule, caspase-3 activity in papillary carcinoma tissue was higher compared to unchanged thyroid tissue of normofollicular structure.
  • In case of a more aggressive behaviour of tumor, enzyme activity in carcinoma tissue did not differ significantly or (in case of extrathyroid spreading of tumor) was decreased compared to that in extratumoral tissue.
  • Сaspase 3 activity was found to be much higher in the tissue of papillary carcinomas of follicular-papillary structure and lower in the tissue of tumors of mixed structure with solid areas, compared to that in the tissue of papillary carcinomas of typical papillary structure.
  • CONCLUSIONS: The data obtainеd in assessing caspase-3 activity suggest that the intensity of spontaneous apoptosis of human papillary thyroid carcinoma cells depends upon the stage and aggressiveness of tumoral process.
  • [MeSH-major] Adenocarcinoma, Papillary / enzymology. Caspase 3 / metabolism
  • [MeSH-minor] Adult. Apoptosis / physiology. Carcinoma. Female. Humans. Male. Neoplasm Staging. Prognosis. Thyroid Neoplasms / enzymology. Thyroid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21270757.001).
  • [ISSN] 1812-9269
  • [Journal-full-title] Experimental oncology
  • [ISO-abbreviation] Exp. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ukraine
  • [Chemical-registry-number] EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Caspase 3; Thyroid cancer, papillary
  •  go-up   go-down


10. Lin HW, Bhattacharyya N: Clinical behavior of follicular variant of papillary thyroid carcinoma: presentation and survival. Laryngoscope; 2010 Apr;120(4):712-6
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical behavior of follicular variant of papillary thyroid carcinoma: presentation and survival.
  • OBJECTIVES/HYPOTHESIS: To determine the prevalence and extent of disease characteristics of the follicular variant of papillary thyroid carcinoma (FV-PTC) and the survival impact of this histopathological diagnosis compared to classical papillary thyroid carcinoma (C-PTC).
  • STUDY DESIGN: Cross-sectional population analysis of a national cancer database.
  • Survival differences according to histology were determined with a Cox proportional hazards model, adjusting for age, sex, T stage, N stage, surgical therapy, and RAI.
  • Although nodal disease prevalence was significantly lower in FV-PTC compared to C-PTC (14.8% vs. 27.8%, respectively; P < .001), T stage was not significantly different (P = .450).
  • Cox regression analysis revealed that advanced age (P < .001), male sex (P < .001), advanced T stage (P < .001), and positive nodal disease (P < .001) were associated with reduced overall survival, whereas histopathological subtype was not (P = .360).
  • [MeSH-major] Adenocarcinoma, Follicular / epidemiology. Carcinoma, Papillary / epidemiology. Thyroid Neoplasms / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20205241.001).
  • [ISSN] 1531-4995
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Agha A, Glockzin G, Woenckhaus M, Dietmaier W, Iesalnieks I, Schlitt HJ: Insular carcinomas of the thyroid exhibit poor prognosis and long-term survival in comparison to follicular and papillary T4 carcinomas. Langenbecks Arch Surg; 2007 Nov;392(6):671-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Insular carcinomas of the thyroid exhibit poor prognosis and long-term survival in comparison to follicular and papillary T4 carcinomas.
  • BACKGROUND: Insular thyroid carcinoma was described as a tumor with aggressive behavior, and patients usually present themselves with an advanced tumor stage.
  • Therefore, in the present study, we compared the survival of patients with advanced insular, follicular, and papillary thyroid cancer.
  • MATERIALS AND METHODS: The clinical behavior of tumors in three groups of patients with T4 thyroid carcinoma--8 patients with insular, 11 patients with follicular, and 21 patients with papillary thyroid carcinomas--was compared.
  • RESULTS: At 3 years, survival was 37.5% (mean 26 months) among patients with insular thyroid carcinoma, 80% (mean 59 months) among those with follicular, and 89% (mean 126 months) among those with papillary thyroid carcinomas (p = 0.007).
  • Disease-free survival in patients without initial distant metastasis was worst in patients with insular thyroid carcinoma (20%) compared to those with follicular (75%) and those with papillary thyroid carcinomas (71%).
  • CONCLUSION: Patients with advanced insular thyroid carcinoma have a poorer outcome in comparison to patients with similar advanced stage who have follicular or papillary thyroid carcinoma.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17216284.001).
  • [ISSN] 1435-2451
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


12. Alevizaki M, Papageorgiou G, Rentziou G, Saltiki K, Marafelia P, Loukari E, Koutras DA, Dimopoulos MA: Increasing prevalence of papillary thyroid carcinoma in recent years in Greece: the majority are incidental. Thyroid; 2009 Jul;19(7):749-54
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increasing prevalence of papillary thyroid carcinoma in recent years in Greece: the majority are incidental.
  • BACKGROUND: New cases of well-differentiated thyroid cancer (DTC) are diagnosed more frequently worldwide.
  • METHODS: During the last 34 years 852 follicular cell-derived DTC cases (83% papillary [PTC], 17% follicular [FTC] carcinoma) presented in the Endocrine Unit of the Department of Clinical Therapeutics in Alexandra Hospital (18.8% men, mean age 42.4 +/- 14.5 years).
  • We recorded the histological type, age at diagnosis, and, in period 3, the type of pre-existing thyroid disease, the stage, and tumor size.
  • [MeSH-major] Carcinoma, Papillary / epidemiology. Thyroid Neoplasms / epidemiology
  • [MeSH-minor] Adenocarcinoma, Follicular / epidemiology. Adenocarcinoma, Follicular / etiology. Adenocarcinoma, Follicular / pathology. Adult. Female. Goiter, Nodular / complications. Greece / epidemiology. Humans. Incidental Findings. Male. Middle Aged. Neoplasm Invasiveness / pathology. Prevalence

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19534620.001).
  • [ISSN] 1557-9077
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Lin JD, Hsueh C, Chao TC: Early recurrence of papillary and follicular thyroid carcinoma predicts a worse outcome. Thyroid; 2009 Oct;19(10):1053-9
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early recurrence of papillary and follicular thyroid carcinoma predicts a worse outcome.
  • BACKGROUND: The occurrence of recurrent papillary and follicular thyroid carcinomas is not unusual.
  • Numerous studies have reported the association between risk factors of initial surgery and recurrence of papillary and follicular thyroid carcinomas.
  • However, we do not have sufficient data to analyze the time of postoperative recurrence associated with therapeutic results and cancer mortality.
  • We hypothesized that an early recurrence of papillary and follicular thyroid cancers implies a rapid growth of cancer resulting in high mortality rate.
  • The investigation included 2148 cases of papillary and follicular thyroid carcinoma, including 325 recurrent cases during the period between 1977 and 2006.
  • Cases with an early recurrence were defined as those in which recurrence occurred in the first year following thyroid surgery.
  • RESULTS: Tumor size, radioactive iodide treatment, multifocality, and tumor-node metastasis stage were independent predictors of recurrence.
  • After a mean follow-up of 8.7 +/- 0.1 years, death due to thyroid cancer was observed to occur in 105 (32.3%) recurrent cases.
  • CONCLUSIONS: Early recurrent papillary and follicular thyroid carcinomas are associated with high mortalities.
  • Therefore, patients whose primary follicular or papillary thyroid carcinoma has features associated with early recurrence should probably receive more aggressive initial treatment.
  • [MeSH-major] Carcinoma, Papillary / pathology. Neoplasm Recurrence, Local / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Follicular / diagnosis. Adenocarcinoma, Follicular / mortality. Adenocarcinoma, Follicular / pathology. Adult. Aged. Biopsy, Fine-Needle. Combined Modality Therapy. Female. Fluorodeoxyglucose F18. Humans. Male. Middle Aged. Neck / ultrasonography. Neoplasm Metastasis / pathology. Positron-Emission Tomography. Predictive Value of Tests. Prognosis. Radiopharmaceuticals. Survival Analysis. Taiwan / epidemiology. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19772423.001).
  • [ISSN] 1557-9077
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


14. Jakubowski M, Hunt JL: BRAF mutational analysis in papillary carcinomas with mixed follicular and papillary growth patterns. Am J Surg Pathol; 2009 Nov;33(11):1590-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BRAF mutational analysis in papillary carcinomas with mixed follicular and papillary growth patterns.
  • BACKGROUND: Current literature suggests that up to 60% of papillary carcinomas have mutations in the BRAF gene.
  • However, follicular variant of papillary carcinoma has a much lower frequency of mutation.
  • Tumors with mixed patterns of growth, including distinctive area of follicular and papillary growth, have not been well studied for the presence of the BRAF gene mutation.
  • DESIGN: Cases of papillary carcinoma were identified with well-defined conventional papillary growth pattern, alongside other areas with follicular growth pattern.
  • The tumor stage was obtained, along with demographic information.
  • In comparing the follicular and the papillary growth patterned areas, the BRAF mutation was concordant in all cases.
  • Four cases had an additional separate focus of microscopic papillary carcinomas.
  • CONCLUSIONS: Papillary carcinomas of the thyroid with papillary growth and areas of follicular growth have a high frequency of BRAF mutations.
  • The BRAF mutational profile is identical in the follicular areas and in the conventional papillary growth areas.
  • These molecular data support the common diagnostic decision that a tumor with any amount of conventional papillary growth should be designated as a conventional papillary carcinoma, regardless of the presence of follicular growth pattern areas.
  • [MeSH-major] Adenocarcinoma, Follicular / genetics. Adenocarcinoma, Papillary / genetics. Mutation. Proto-Oncogene Proteins B-raf / genetics. Thyroid Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19738460.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  •  go-up   go-down


15. Handkiewicz-Junak D, Czarniecka A, Jarzab B: Molecular prognostic markers in papillary and follicular thyroid cancer: Current status and future directions. Mol Cell Endocrinol; 2010 Jun 30;322(1-2):8-28
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular prognostic markers in papillary and follicular thyroid cancer: Current status and future directions.
  • Gene expression profiling shows that, by gene signature, the difference between BRAF-positive and BRAF-negative PTC is so distinct that BRAF-positive cancer may be regarded as a molecular subtype of papillary thyroid cancer (PTC).
  • We estimate that 31% of all PTC patients and 39% of those diagnosed with stage I-II disease will face the risk of overtreatment if the decision will be based on the BRAF-positivity of their tumors.
  • Considering this, in the review we summarize the present status of knowledge on other prognosis-related gene expression changes in papillary and follicular cancer and relate them to he tumor's biology.
  • [MeSH-major] Adenocarcinoma, Follicular / metabolism. Carcinoma, Papillary / metabolism. Thyroid Neoplasms / metabolism

  • Genetic Alliance. consumer health - Thyroid cancer, follicular.
  • Genetic Alliance. consumer health - Thyroid cancer, papillary.
  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20138116.001).
  • [ISSN] 1872-8057
  • [Journal-full-title] Molecular and cellular endocrinology
  • [ISO-abbreviation] Mol. Cell. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 3.6.5.2 / ras Proteins
  • [Number-of-references] 259
  •  go-up   go-down


16. Ito Y, Ichihara K, Masuoka H, Fukushima M, Inoue H, Kihara M, Tomoda C, Higashiyama T, Takamura Y, Kobayashi K, Miya A, Miyauchi A: Establishment of an intraoperative staging system (iStage) by improving UICC TNM classification system for papillary thyroid carcinoma. World J Surg; 2010 Nov;34(11):2570-80
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment of an intraoperative staging system (iStage) by improving UICC TNM classification system for papillary thyroid carcinoma.
  • BACKGROUND: Papillary thyroid carcinoma generally has an indolent nature, but cases demonstrating certain features are progressive.
  • UICC TNM classification is the most widely adopted system to evaluate the biological behavior of this carcinoma, but it is doubtful whether this system that evaluates only the preoperative findings can appropriately reflect patient prognosis.
  • METHODS: We investigated the prognoses of 5,911 patients with papillary carcinoma without distant metastasis at diagnosis who underwent initial surgery between January 1987 and January 2005 and compared the utility of iStage with that of conventional classification systems, such as UICC Stage, MACIS score (>7 and ≤7), AMES, and CIH classification.
  • RESULTS: Disease-free survival (DFS) and cause-specific survival (CSS) of patients with stage IVA were better than those of high-risk patients on other systems, and CSS of stage III patients did not differ from stage IVA patients.
  • We established iStage by improving the original UICC stage.
  • Appropriate intraoperative evaluation is mandatory to grade biological characteristics, including prognosis, of papillary carcinoma.
  • [MeSH-major] Adenocarcinoma, Papillary / pathology. Neoplasm Staging / methods. Thyroid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] World J Surg. 2011 Feb;35(2):472
  • (PMID = 20625728.001).
  • [ISSN] 1432-2323
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Chen MY, Jung SM, Ng KK, Chang TC: Pulmonary papillary serous adenocarcinoma with intraperitoneal and ovarian tumors: identification of primary site. A case report. Int J Gynecol Cancer; 2006 Jan-Feb;16 Suppl 1:231-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary papillary serous adenocarcinoma with intraperitoneal and ovarian tumors: identification of primary site. A case report.
  • Papillary serous adenocarcinoma has been recognized as a highly malignant ovarian cancer and is also not uncommonly seen in primary lung cancer.
  • We present a patient who was initially diagnosed and treated as stage IV papillary serous ovarian cancer with diffuse pulmonary metastases.
  • Only transient symptomatic improvement was achieved after standard chemotherapy for ovarian cancer, and then she died of respiratory distress during treatment.
  • Poor tumor response to chemotherapy prompted us to reevaluate the previous bronchoscopic biopsy, and immunohistochemical studies, which were cytokeratin (CK) 7 positive, CK20 negative, and thyroid transcription factor-1 (TTF-1)-positive, provided irrefutable evidences for the diagnosis of primary lung cancer.
  • [MeSH-major] Adenocarcinoma, Papillary / pathology. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lung Neoplasms / pathology. Ovarian Neoplasms / pathology. Peritoneal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16515596.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / KRT20 protein, human; 0 / KRT7 protein, human; 0 / Keratin-20; 0 / Keratin-7; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1; 68238-35-7 / Keratins; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


18. Baek SK, Jung KY, Kang SM, Kwon SY, Woo JS, Cho SH, Chung EJ: Clinical risk factors associated with cervical lymph node recurrence in papillary thyroid carcinoma. Thyroid; 2010 Feb;20(2):147-52
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical risk factors associated with cervical lymph node recurrence in papillary thyroid carcinoma.
  • BACKGROUND: Recurrence of regional cervical lymph nodes in patients with papillary thyroid carcinoma (PTC) is not uncommon, and is an important factor affecting the quality of life.
  • RESULTS: Tumor size >2 cm, presence of extrathyroid tumor spread, high T stage, and presence of lymph node metastasis were associated with regional lymph node recurrence in univariate analysis (p < 0.05).
  • Among them, only the N stage was significantly associated with regional recurrence in multivariate analysis (p < 0.05).
  • However, if any risk factors for regional recurrence, including large tumor size, presence of extrathyroid spread, high T stage, and presence of lymph node metastasis, are detected by preoperative and intraoperative evaluation, a systematic compartment-oriented lymphadenectomy should be considered because of the high possibility of regional recurrence.
  • [MeSH-major] Carcinoma, Papillary / pathology. Neoplasm Recurrence, Local / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Papillary / pathology. Adenocarcinoma, Papillary / surgery. Adolescent. Adult. Aged. Aged, 80 and over. Child. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Lymph Nodes / pathology. Lymphatic Metastasis / pathology. Male. Middle Aged. Neck Dissection. Prognosis. Retrospective Studies. Risk Factors. Thyroidectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19785522.001).
  • [ISSN] 1557-9077
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


19. Kitahara S, Ito T, Hamatani S, Shibuya K, Shiba T: Thyroid papillary carcinoma recurring as squamous cell carcinoma: report of a case. Surg Today; 2006;36(2):171-4
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thyroid papillary carcinoma recurring as squamous cell carcinoma: report of a case.
  • We report a case of local squamous cell carcinoma recurrence of thyroid papillary carcinoma, 4 years after subtotal thyroidectomy, in an 82-year-old woman.
  • The papillary cancer of the right thyroid was histopathologically classified as T2a, N0, M0, Ex1; pT2a, pN1b, pEx1; Stage III.
  • The tumor was judged cytologically to be class III, defined as a suspicious malignancy and, after reoperation, it was diagnosed histopathologically as papillary carcinoma recurrence with extensive squamous metaplasia.
  • The recurrent papillary carcinoma was thought to have changed to a squamous cell carcinoma because most of the tumor was occupied by atypical squamous cells, with a small amount of glandular tissue.
  • The primary tumor was histologically diagnosed as a well-differentiated papillary carcinoma at the initial operation.
  • It contained numerous tall neoplastic cells with eosinophilic granules and pseudostratified nuclei, indicating that it could potentially transform into squamous cell carcinoma.
  • We report this case as an example of how squamous cell carcinoma of the thyroid can develop.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Carcinoma, Squamous Cell / pathology. Neoplasm Recurrence, Local / pathology. Neoplasms, Second Primary / pathology. Thyroid Neoplasms / pathology. Thyroidectomy / methods

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16440166.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


20. Pan YF, Zhang XH, Ye GH, Lin BR, Chen XM, Jia XJ, Zhou SM, Wang OC: [One stage thyroidectomy and bilateral neck dissection for well-differentiated thyroid carcinoma]. Zhonghua Zhong Liu Za Zhi; 2006 May;28(5):389-92
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [One stage thyroidectomy and bilateral neck dissection for well-differentiated thyroid carcinoma].
  • OBJECTIVE: To investigate the indications, safety and difficulties of one stage thyroidectomy and bilateral neck lymph node dissection for well-differentiated thyroid carcinoma.
  • METHODS: A retrospective review was carried out in 36 well-differentiated thyroid carcinoma patients so treated from 1990 to 2004.
  • CONCLUSION: The procedure of one-stage thyroidectomy and bilateral neck lymph node dissection for well-differentiated thyroid carcinoma is safe, as it is mandatory that at least one unilateral internal jugular vein should be preserved; one unilateral recurrent laryngeal nerves and accessory nerves should not be injured.
  • Well-differentiated thyroid carcinoma patients whose bilateral cervical lymph nodes are clinically suspected to be positive (obviously enlarged, hard, purplish grapelike lymph node) or are confirmed pathologically to be positive are indications for one-stage thyroidectomy and bilateral neck lymph node dissection.
  • It is of utmost importance that not only the cancer be completely resected but the function of the organs be preserved.
  • [MeSH-major] Carcinoma, Papillary / surgery. Lymph Nodes / pathology. Neck Dissection. Thyroid Neoplasms / surgery. Thyroidectomy / methods
  • [MeSH-minor] Adenocarcinoma, Follicular / secondary. Adenocarcinoma, Follicular / surgery. Adult. Female. Follow-Up Studies. Humans. Hypothyroidism / etiology. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local. Postoperative Complications. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17045009.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


21. Lang B, Lo CY, Chan WF, Lam KY, Wan KY: Restaging of differentiated thyroid carcinoma by the sixth edition AJCC/UICC TNM staging system: stage migration and predictability. Ann Surg Oncol; 2007 May;14(5):1551-9
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Restaging of differentiated thyroid carcinoma by the sixth edition AJCC/UICC TNM staging system: stage migration and predictability.
  • BACKGROUND: The AJCC/UICC TNM staging system (TNM) is a widely accepted system for differentiated thyroid carcinoma (DTC).
  • The objective of the present study was to evaluate the potential changes in cancer-specific survival (CSS) after reclassification from fifth to sixth edition TNM.
  • Significant differences in CSS were observed between stage III (fifth edition) and stage III (sixth edition) and between stage IV (fifth edition) and stage IVA (sixth edition).
  • [MeSH-major] Thyroid Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / secondary. Adenocarcinoma / therapy. Adenocarcinoma, Follicular / pathology. Adenocarcinoma, Follicular / secondary. Adenocarcinoma, Follicular / therapy. Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Papillary / pathology. Carcinoma, Papillary / secondary. Carcinoma, Papillary / therapy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / therapy. Cell Differentiation. Child. Cohort Studies. Female. Follow-Up Studies. Humans. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Prognosis. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2007 May;14(5):1521-2 [17294077.001]
  • (PMID = 17318278.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Rumiantseva UV, Il'in AA, Rumiantseva PO, Medvedev VS, Abrosimov AIu, Zaletaev DV: [Familial well-differentiated thyroid carcinoma]. Vopr Onkol; 2006;52(1):42-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Familial well-differentiated thyroid carcinoma].
  • Medical Research Institute of Radiology, Russian Academy Forty-eight cases of familial disease (24 families) (4.3%) were identified among 1,118 patients with well-differentiated thyroid carcinoma who had been either examined or treated at the Clinic of Medical Research Institute of Radiology (1995-2004).
  • In 86% of the study group, papillary thyroid carcinoma (PTC) was associated with tumor of the identical histological pattern while the remaining families revealed association with follicular or medullary thyroid cancer.
  • Carcinoma inheritable from mother was the most frequent (75%).
  • No differences in manifestation, histological pattern, stage or clinical course were established following a detailed evaluation of clinico-morphological data on 43 familial and 172 sporadic (control) cases in both groups.
  • The analysis pointed to a significantly higher incidence of concomitant thyroid pathology in the familial thyroid cancer group.
  • [MeSH-major] Thyroid Neoplasms / genetics
  • [MeSH-minor] Adenocarcinoma, Follicular / genetics. Adult. Aged. Alanine. Carcinoma, Medullary / genetics. Carcinoma, Papillary / genetics. Female. Glycine. Humans. Male. Middle Aged. Proto-Oncogene Proteins c-ret / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. GLYCINE .
  • Hazardous Substances Data Bank. (L)-ALANINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16715702.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-ret; EC 2.7.10.1 / RET protein, human; OF5P57N2ZX / Alanine; TE7660XO1C / Glycine
  •  go-up   go-down


23. Konturek A, Barczyński M, Cichoń S, Pituch-Noworolska A, Jonkisz J, Cichoń W: Significance of vascular endothelial growth factor and epidermal growth factor in development of papillary thyroid cancer. Langenbecks Arch Surg; 2005 Jun;390(3):216-21
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of vascular endothelial growth factor and epidermal growth factor in development of papillary thyroid cancer.
  • Several recent reports have shown overexpression of VEGF and EGF in papillary thyroid cancer (PTC).
  • However, the intensity of their expression is variable, depending on the stage of the disease.
  • The highest intensity of VEGF expression is characteristic for low-stage T1N0M0 disease, whereas the highest intensity of EGF expression is more often found at locally advanced pT3 and pT4N1M0 stages of the disease.

  • Genetic Alliance. consumer health - Thyroid cancer, papillary.
  • Genetic Alliance. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15690202.001).
  • [ISSN] 1435-2443
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A; 62229-50-9 / Epidermal Growth Factor
  •  go-up   go-down


24. Freschi G, Landi L, Castagnoli A, Taddei A, Bechi P, Bucciarelli G: Advanced thyroid carcinoma: an experience of 385 cases. Eur J Surg Oncol; 2006 Jun;32(5):577-82
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced thyroid carcinoma: an experience of 385 cases.
  • AIMS: To report clinical outcomes of a large series of cases with advanced thyroid cancer.
  • STUDY DESIGN: Three hundred and eighty-five patients at the UICC stages III and IV were selected for the study with thyroid cancer.
  • RESULTS: Papillary carcinoma and sclerosing carcinoma have better survival than the Hürthle cell and insular types.
  • CONCLUSIONS: Surgical treatment is the primary treatment of thyroid carcinoma.
  • The combined treatments of surgery, metabolic beam therapy, suppressive hormone therapy, radiotherapy and chemotherapy cure a high percentage of patients with the tumour at an advanced stage.
  • [MeSH-major] Carcinoma / surgery. Thyroid Neoplasms / surgery. Thyroidectomy
  • [MeSH-minor] Adenocarcinoma / surgery. Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Agents, Hormonal / therapeutic use. Carcinoma, Papillary / surgery. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Radiotherapy, Adjuvant. Risk Assessment. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16644177.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal
  •  go-up   go-down


25. Savin S, Cvejic D, Isic T, Paunovic I, Tatic S, Havelka M: Thyroid peroxidase and galectin-3 immunostaining in differentiated thyroid carcinoma with clinicopathologic correlation. Hum Pathol; 2008 Nov;39(11):1656-63
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thyroid peroxidase and galectin-3 immunostaining in differentiated thyroid carcinoma with clinicopathologic correlation.
  • Thyroperoxidase and galectin-3 have been reported as useful immunohistochemical markers of thyroid malignancy.
  • In this study, we evaluated the relationship between immunohistochemical staining results for these markers and clinicopathologic features of patients with differentiated thyroid cancer.
  • A total of 193 archival thyroid samples including 28 follicular adenomas, 18 follicular carcinomas, and 147 papillary carcinomas with 114 adjacent thyroid tissues were analyzed by immunohistochemistry.
  • The sensitivity for diagnosis of differentiated thyroid carcinoma was 86.1% for thyroperoxidase and 82.4% for galectin-3, whereas the combination of both markers increased the sensitivity up to 94.5%.
  • Furthermore, tumor size, nodal involvement, extrathyroidal invasion, and high tumor-node-metastasis stage in patients with papillary carcinoma were related to thyroperoxidase absence and high galectin-3 expression in most cases (P < .05).
  • In patients with follicular carcinoma, the extent of invasiveness was associated with galectin-3 positivity.
  • Thus, expression of these markers is related to more or less aggressive biological behavior of differentiated thyroid carcinomas.
  • Although thyroperoxidase presence may indicate favorable prognosis of papillary cancer, expression of galectin-3 illustrates the potential importance of this protein in the pathogenesis and/or progression of differentiated thyroid carcinomas.
  • [MeSH-major] Galectin 3 / metabolism. Iodide Peroxidase / metabolism. Thyroid Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma, Follicular / metabolism. Adenocarcinoma, Follicular / pathology. Adenoma / metabolism. Adenoma / pathology. Adult. Biomarkers, Tumor / metabolism. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. Female. Humans. Immunohistochemistry. Male. Middle Aged. Sensitivity and Specificity. Thyroid Gland / metabolism. Thyroid Gland / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18657294.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Galectin 3; EC 1.11.1.8 / Iodide Peroxidase
  •  go-up   go-down


26. Kebebew E, Peng M, Reiff E, Duh QY, Clark OH, McMillan A: Diagnostic and prognostic value of angiogenesis-modulating genes in malignant thyroid neoplasms. Surgery; 2005 Dec;138(6):1102-9; discussion 1109-10
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic and prognostic value of angiogenesis-modulating genes in malignant thyroid neoplasms.
  • We postulated that expression analysis of genes that modulate angiogenesis would identify differentially expressed genes that would help to distinguish benign from malignant thyroid neoplasms and serve as markers of aggressive differentiated thyroid cancer.
  • METHODS: A complementary DNA (cDNA) array with 96 genes that modulate angiogenesis was used to identify differentially expressed genes (2-fold higher or lower) in malignant versus benign thyroid neoplasms.
  • Real-time quantitative polymerase chain reaction was used to confirm cDNA array expression data in 123 patients (4 normal thyroid, 26 hyperplastic nodules, 27 follicular adenomas, 23 follicular cancers, 18 follicular variant of papillary cancers, 25 papillary cancers).
  • RESULTS: Twenty-two genes were upregulated in malignant thyroid neoplasms by cDNA array analysis, but only 13 genes had higher messenger RNA (mRNA) expression levels in malignant than in benign thyroid neoplasms by real-time quantitative polymerase chain reaction (P < or = .04).
  • Of the 13 differentially expressed genes, the combined use of angiopoietin 2 (ANGPT2) and tissue inhibitor of metalloproteinase 1 (TIMP1) mRNA expression levels was best for distinguishing malignant from benign thyroid neoplasms, with a sensitivity of 90%, specificity of 85%, positive predictive value of 75%, and negative predictive value of 94%.
  • Epidermal growth factor receptor and ephrin B2 mRNA expression was elevated in higher TNM stage neoplasms and in patients with high-risk AMES (Age, distant Metastasis, Extrathyroidal invasion, and tumor Size) differentiated thyroid cancers (P < or = .005).
  • CONCLUSIONS: Angiopoietin 2 and tissue inhibitor of metalloproteinase 1 are diagnostic markers of malignant thyroid nodules and could improve the diagnostic accuracy of FNA biopsy.
  • Epidermal growth factor receptor and ephrin B2 are markers of aggressive differentiated thyroid cancer.
  • [MeSH-major] Adenocarcinoma, Follicular / genetics. Adenoma / genetics. Angiogenic Proteins / genetics. Carcinoma, Papillary / genetics. Carcinoma, Papillary, Follicular / genetics. Thyroid Neoplasms / genetics. Thyroid Nodule / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16360397.001).
  • [ISSN] 0039-6060
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenic Proteins
  •  go-up   go-down


27. Yasmeen S, Cress R, Romano PS, Xing G, Berger-Chen S, Danielsen B, Smith LH: Thyroid cancer in pregnancy. Int J Gynaecol Obstet; 2005 Oct;91(1):15-20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thyroid cancer in pregnancy.
  • OBJECTIVE: To compare stage at diagnosis, treatment and survival among pregnant women with thyroid cancer to non-pregnant women with thyroid cancer, and to assess the impact of treatment on maternal and perinatal outcomes.
  • METHODS: A database containing maternal and newborn discharge records linked to the California Cancer Registry was queried to obtain information on all thyroid cancers from 1991-1999.
  • Women with thyroid cancer occurring during pregnancy were compared to age-matched non-pregnant women with thyroid cancer.
  • RESULTS: 595 cases of thyroid cancers were identified (129 antepartum and 466 postpartum).
  • About 64% of thyroid cancers were diagnosed at stage 2 among pregnant women versus 58% among non-pregnant controls.
  • The odds of thyroid cancer were 1.5 times higher among Asian/Pacific Islanders than among Non-Hispanic White women.
  • Pregnancy had no significant effect on mortality after diagnosis of thyroid cancer.
  • CONCLUSIONS: Thyroid cancer discovered during or after pregnancy does not appear to have a significant impact on the prognosis of the disease.
  • [MeSH-minor] Adenocarcinoma, Follicular / mortality. Adenocarcinoma, Follicular / pathology. Adenocarcinoma, Follicular / therapy. Adenocarcinoma, Papillary / mortality. Adenocarcinoma, Papillary / pathology. Adenocarcinoma, Papillary / therapy. Adult. Female. Humans. Pregnancy. Prognosis. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Pregnancy.
  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Postpartum Care.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16085061.001).
  • [ISSN] 0020-7292
  • [Journal-full-title] International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
  • [ISO-abbreviation] Int J Gynaecol Obstet
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Collini P, Mattavelli F, Spinelli C, Massimino M: Treatment of sporadic nonmedullary thyroid carcinomas in pediatric age. Expert Rev Anticancer Ther; 2007 Jan;7(1):23-30
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of sporadic nonmedullary thyroid carcinomas in pediatric age.
  • Nonmedullary thyroid carcinomas are rare malignancies in pediatric ages.
  • The vast majority of them are papillary carcinomas with an overall survival of approximately 100%.
  • Their outcome is independent of strong prognostic factors of adults, such as papillary carcinoma histological subtype, invasion into soft tissue of the neck, presence and site of distant metastases, relapse and type of surgery.
  • In most institutions, the therapy of choice for all pediatric thyroid carcinomas is the radical approach, aimed at the eradication at diagnosis of all clinical and subclinical neoplastic foci, both at thyroid, lymph node and distant level.
  • It consists of total thyroidectomy and lymphadenectomy in children with clinically evident lymph-node metastases, followed by radioactive iodine therapy independent of histotype and stage.
  • Recently, owing also to the high sensitivity to hormonal manipulation shown by pediatric papillary carcinomas, a conservative approach has been proposed for selected cases, consisting of the removal of only the grossly detectable disease followed by thyroid-stimulating hormone-suppressive hormonal therapy to control subclinical disease.
  • Today, the existence of two therapeutic approaches, radical versus conservative therapy, should be considered whenever treating a child or adolescent with a nonmedullary thyroid carcinoma.
  • The future tasks include the stratification of thyroid carcinomas into low- and high-risk cases, also including their molecular alterations and the possibility of a molecularly targeted therapy against tyrosine kinases involved in the pathogenesis of thyroid carcinomas.
  • [MeSH-major] Carcinoma, Papillary / surgery. Thyroid Neoplasms / therapy
  • [MeSH-minor] Adenocarcinoma, Follicular / surgery. Adenocarcinoma, Follicular / therapy. Child. Humans. Lymph Node Excision

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17187518.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 28
  •  go-up   go-down


29. Enewold L, Zhu K, Ron E, Marrogi AJ, Stojadinovic A, Peoples GE, Devesa SS: Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005. Cancer Epidemiol Biomarkers Prev; 2009 Mar;18(3):784-91
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005.
  • Thyroid cancer incidence has been rising in the United States, and this trend has often been attributed to heightened medical surveillance and the use of improved diagnostics.
  • Thyroid cancer incidence varies by sex and race/ethnicity, and these factors also influence access to and utilization of healthcare.
  • We therefore examined thyroid cancer incidence rates by demographic and tumor characteristics based on 48,403 thyroid cancer patients diagnosed during 1980-2005 from the Surveillance, Epidemiology and End Results program of the National Cancer Institute.
  • Papillary carcinoma was the only histologic type for which incidence rates increased consistently among all racial/ethnic groups.
  • Subsequent analyses focused on the 39,706 papillary thyroid cancers diagnosed during this period.
  • Papillary carcinoma rates increased most rapidly among females.
  • The increases were most rapid for localized stage and small tumors; however, rates also increased for large tumors and tumors of regional and distant stage.
  • Since 1992-1995, half the overall increase in papillary carcinoma rates was due to increasing rates of very small (<or=1.0 cm) cancers, 30% to cancers 1.1 to 2 cm, and 20% to cancers>2 cm.
  • Medical surveillance and more sensitive diagnostic procedures cannot completely explain the observed increases in papillary thyroid cancer rates.
  • [MeSH-major] Thyroid Neoplasms / epidemiology
  • [MeSH-minor] Adenocarcinoma, Follicular / epidemiology. Adenocarcinoma, Follicular / ethnology. Adenocarcinoma, Follicular / pathology. Adult. Aged. Carcinoma, Papillary / epidemiology. Carcinoma, Papillary / ethnology. Carcinoma, Papillary / pathology. Demography. Female. Humans. Incidence. Male. Middle Aged. Risk Factors. SEER Program. Sex Factors. Time Factors. United States / epidemiology

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Epidemiol. 2000 Jan;10(1):24-30 [10658686.001]
  • [Cites] Cancer Causes Control. 2008 Dec;19(10):1183-91 [18543070.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Feb;87(2):489-99 [11836274.001]
  • [Cites] Thyroid. 2002 Feb;12(2):141-9 [11916283.001]
  • [Cites] Am J Epidemiol. 1980 Dec;112(6):764-74 [7457469.001]
  • [Cites] Biochem Biophys Res Commun. 1987 Dec 16;149(2):707-11 [2827649.001]
  • [Cites] Am J Epidemiol. 1994 Apr 15;139(8):747-60 [8178788.001]
  • [Cites] Am J Epidemiol. 1995 Feb 15;141(4):300-4 [7840107.001]
  • [Cites] Radiat Res. 1995 Mar;141(3):259-77 [7871153.001]
  • [Cites] Cancer Causes Control. 1999 Apr;10(2):143-55 [10231163.001]
  • [Cites] Thyroid. 2004 Dec;14(12):1056-60 [15650358.001]
  • [Cites] Clin Endocrinol (Oxf). 2005 Feb;62(2):156-62 [15670190.001]
  • [Cites] Obstet Gynecol. 2005 Dec;106(6):1365-71 [16319264.001]
  • [Cites] Thyroid. 2006 Jan;16(1):47-53 [16487013.001]
  • [Cites] Eur J Endocrinol. 2006 May;154(5):599-611 [16645005.001]
  • [Cites] JAMA. 2006 May 10;295(18):2164-7 [16684987.001]
  • [Cites] JAMA. 2006 May 10;295(18):2179-82 [16684990.001]
  • [Cites] Br J Cancer. 2006 Aug 7;95(3):366-70 [16832414.001]
  • [Cites] JAMA. 2006 Sep 20;296(11):1350; author reply 1350 [16985224.001]
  • [Cites] Eur J Radiol. 2006 Oct;60(1):67-9 [16787731.001]
  • [Cites] Thyroid. 2006 Oct;16(10):1033-40 [17042690.001]
  • [Cites] BMC Cancer. 2006;6:284 [17156468.001]
  • [Cites] Eur J Cancer. 2007 Mar;43(5):891-900 [17289376.001]
  • [Cites] J Am Coll Radiol. 2007 May;4(5):272-84 [17467608.001]
  • [Cites] Am J Epidemiol. 2007 Nov 15;166(10):1140-9 [17855390.001]
  • [Cites] CMAJ. 2007 Nov 20;177(11):1357-61 [18025426.001]
  • [Cites] CMAJ. 2007 Nov 20;177(11):1383-4 [18025430.001]
  • [Cites] Hum Reprod. 2008 Feb;23(2):451-6 [18065402.001]
  • [Cites] Am J Epidemiol. 2008 Jan 15;167(2):219-29 [17965111.001]
  • [Cites] Ann Surg Oncol. 2008 Apr;15(4):1169-76 [18246401.001]
  • [Cites] Thyroid. 2008 Apr;18(4):461-4 [18346005.001]
  • [Cites] Cancer Causes Control. 2008 Aug;19(6):585-93 [18240001.001]
  • [Cites] Health Phys. 2008 Nov;95(5):502-7 [18849682.001]
  • [Cites] Br J Cancer. 2001 Nov 2;85(9):1335-9 [11720471.001]
  • (PMID = 19240234.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z99 CA999999
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS104589; NLM/ PMC2676561
  •  go-up   go-down


30. Shulutko AM, Semikov VI, Griaznov VI, Chakvetadze NG, Popov SV: [Clinical value, diagnosis and treatment of thyroid differentiated microcarcinoma]. Khirurgiia (Mosk); 2007;(12):4-10
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical value, diagnosis and treatment of thyroid differentiated microcarcinoma].
  • Results of surgical treatment of 240 patients with thyroid differentiated microcarcinoma (less 1 cm in diameter) are analyzed.
  • Papillary and follicular tumor was diagnosed at 212 (88.3%) and 28 (11.7%) respectively.
  • In some cases microcarcinoma had aggressive clinical course: at 10.8% patients the tumor was extended beyond the bounds of thyroid capsule (T3), at 2.1% patients the primary symptoms of disease were metastases into cervical nodes.
  • Microcarcinoma is regarded as early stage of thyroid gland cancer.
  • [MeSH-major] Adenocarcinoma, Follicular / diagnosis. Adenocarcinoma, Papillary / diagnosis. Thyroid Neoplasms / diagnosis. Thyroidectomy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18163106.001).
  • [ISSN] 0023-1207
  • [Journal-full-title] Khirurgiia
  • [ISO-abbreviation] Khirurgiia (Mosk)
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


31. Smailyte G, Miseikyte-Kaubriene E, Kurtinaitis J: Increasing thyroid cancer incidence in Lithuania in 1978-2003. BMC Cancer; 2006;6:284
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increasing thyroid cancer incidence in Lithuania in 1978-2003.
  • BACKGROUND: The aim of this paper is to analyze changes in thyroid cancer incidence trends in Lithuania during the period 1978-2003 using joinpoint regression models, with special attention to the period 1993-2003.
  • METHODS: The study was based on all cases of thyroid cancer reported to the Lithuanian Cancer Registry between 1978 and 2003.
  • A change in the trend occurred in which a significant increase changed to a dramatic increase in thyroid cancer incidence rates.
  • Papillary carcinoma and stage I thyroid cancer increases over this period were mainly responsible for the pattern of changes in trend in recent years.
  • CONCLUSION: A moderate increase in thyroid cancer incidence has been observed in Lithuania between the years 1978 and 2000.
  • An accelerated increase in thyroid cancer incidence rates took place in the period 2000-2003.
  • It seems that the increase in thyroid cancer incidence can be attributed mainly to the changes in the management of non palpable thyroid nodules with growing applications of ultrasound-guided fine needle aspiration biopsy in clinical practice.
  • [MeSH-major] Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / epidemiology

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Stat Med. 2000 Feb 15;19(3):335-51 [10649300.001]
  • [Cites] Cancer Causes Control. 2000 Feb;11(2):137-44 [10710197.001]
  • [Cites] Thyroid. 2001 May;11(5):483-6 [11396706.001]
  • [Cites] Br J Cancer. 2001 Nov 2;85(9):1335-9 [11720471.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Jan;11(1):51-7 [11815401.001]
  • [Cites] Eur J Cancer. 2003 Feb;39(3):295-9 [12565980.001]
  • [Cites] J Radiol Prot. 2006 Jun;26(2):127-40 [16738412.001]
  • [Cites] Eur J Cancer. 2003 Sep;39(13):1912-9 [12932671.001]
  • [Cites] Eur J Endocrinol. 2004 Feb;150(2):133-9 [14763910.001]
  • [Cites] Exp Clin Endocrinol Diabetes. 1998;106 Suppl 3:S38-44 [9865553.001]
  • [Cites] Thyroid. 2004 Dec;14(12):1056-60 [15650358.001]
  • [Cites] Clin Endocrinol (Oxf). 2005 Feb;62(2):156-62 [15670190.001]
  • [Cites] JAMA. 2006 May 10;295(18):2164-7 [16684987.001]
  • [Cites] Cancer Causes Control. 2003 Feb;14(1):13-7 [12708720.001]
  • (PMID = 17156468.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1764427
  •  go-up   go-down


32. Dralle H, Lorenz K, Machens A: [Surgery of thyroid carcinoma]. Chirurg; 2009 Nov;80(11):1069-82; quiz 1083
Hazardous Substances Data Bank. Calcitonin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgery of thyroid carcinoma].
  • The 5 main types of thyroid cancer (papillary, PTC, follicular, FTC, poorly differentiated, PDTC undifferentiated, UTC, medullary, MTC) not only differ regarding morphology, pathogenesis, genetics,and pathophysiology (iodine metabolism, thyroglobulin and calcitonin production), but also concerning tumor biology, metastatic behavior (lymphogenous, locally invasive and hematogenous routes) and prognosis.
  • Knowledge of these features is the basis of the surgical concept of one or two-stage thyroidectomy, the exceptions and the concept of locoregional lymph node dissection.
  • [MeSH-major] Adenocarcinoma, Follicular / surgery. Carcinoma / surgery. Carcinoma, Medullary / surgery. Carcinoma, Papillary / surgery. Lymph Node Excision / methods. Thyroid Neoplasms / surgery. Thyroidectomy / methods

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19902289.001).
  • [ISSN] 1433-0385
  • [Journal-full-title] Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 9007-12-9 / Calcitonin
  •  go-up   go-down


33. Spriano G, Ruscito P, Pellini R, Appetecchia M, Roselli R: Pattern of regional metastases and prognostic factors in differentiated thyroid carcinoma. Acta Otorhinolaryngol Ital; 2009 Dec;29(6):312-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pattern of regional metastases and prognostic factors in differentiated thyroid carcinoma.
  • The meaning of nodal metastases in well-differentiated thyroid carcinoma is controversial.
  • The Authors analyse the impact of lymphatic spread reviewing 1503 cases of well-differentiated thyroid carcinoma treated at the National Cancer Institute of Rome between 1988 and 2005, in order to detect significant prognostic factors through multivariate analysis.
  • Overall, 462 cases of locally advanced well-differentiated thyroid carcinoma, were considered.
  • A multivariate analysis of a subgroup, comprising 97 N+ consecutive cases of well-differentiated thyroid carcinoma, previously untreated, was performed to study prognostic factors for local (N+) and distant (M+) metastasis in well-differentiated thyroid carcinoma.
  • Of the 97 cases, 88 were submitted to surgery for a large well-differentiated thyroid carcinoma, 9 for occult differentiated thyroid carcinoma.
  • After surgery, 12 patients were lost to follow-up, 8 resulted pathologically negative, therefore only 77 cases of pN1 well-differentiated thyroid carcinoma were studied.
  • Considering all cases of well-differentiated thyroid carcinoma, 10-year-overall survival was 58.7% for locally advanced well-differentiated thyroid carcinoma, compared to 94.8% in low stage cases.
  • The Authors present a retrospective study of 77 patients with primary differentiated thyroid carcinoma, submitted to thyroidectomy and neck dissection aimed at analysing distribution of nodal metastases according to Robbins' levels classification and defining their prognostic value.
  • All N1b cases, retrospectively reviewed (n. 77), presented clinical and histological evidence of neck nodes metastases from differentiated thyroid carcinoma; histological reports indicated tumour localisation and topographical distribution of metastases; papillary carcinoma was the most common type (72 cases), followed by follicular carcinoma (5 cases).
  • Statistically significant prognostic factors for distant metastases and recurrence on the neck were follicular carcinoma (p < 0.01) and extra-capsular spread (p < 0.001).
  • In the Authors' experience, histological grade of differentiation, wide tumour excision and neck dissection, in cases of N1b well-differentiated thyroid carcinoma, without residual disease (R1, R2), in the central and lateral neck, are determinant prognostic factors.
  • [MeSH-major] Carcinoma, Papillary / secondary. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Follicular. Adolescent. Adult. Aged. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Prognosis. Retrospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Laryngoscope. 1992 May;102(5):486-91 [1573942.001]
  • [Cites] Surgery. 2006 Dec;140(6):1050-4; discussion 1054-5 [17188156.001]
  • [Cites] J Exp Clin Cancer Res. 1997 Sep;16(3):333-5 [9387910.001]
  • [Cites] Br J Surg. 1998 Feb;85(2):252-4 [9501829.001]
  • [Cites] Otolaryngol Clin North Am. 1998 Oct;31(5):823-31 [9735110.001]
  • [Cites] World J Surg. 1999 Sep;23(9):970-3; discussion 973-4 [10449830.001]
  • [Cites] Cancer. 1975 Sep;36(3):1138-46 [1182668.001]
  • [Cites] Ann Surg. 1976 Nov;184(5):541-53 [984923.001]
  • [Cites] Am J Surg. 1978 Jul;136(1):107-12 [567016.001]
  • [Cites] Cancer. 1979 Mar;43(3):810-20 [427722.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2006 Jun;132(6):650-4 [16785411.001]
  • [Cites] Vestn Khir Im I I Grek. 2005;164(6):48-51 [16792315.001]
  • [Cites] Am J Med. 1981 Mar;70(3):511-8 [7211893.001]
  • [Cites] Cancer. 1985 Feb 15;55(4):794-804 [3967174.001]
  • [Cites] Surgery. 1985 Dec;98(6):1171-8 [4071392.001]
  • [Cites] Cancer. 1986 Apr 1;57(7):1405-14 [3948123.001]
  • [Cites] Mayo Clin Proc. 1986 Dec;61(12):978-96 [3773569.001]
  • [Cites] Surg Clin North Am. 1987 Apr;67(2):251-61 [3551147.001]
  • [Cites] Am J Surg. 1990 Oct;160(4):344-7 [2221232.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1991 Jun;117(6):601-5 [2036180.001]
  • [Cites] Folia Med (Plovdiv). 2006;48(1):17-22 [16918050.001]
  • [Cites] Laryngoscope. 2006 Nov;116(11):2081-5 [17075398.001]
  • [Cites] J Surg Oncol. 2006 Dec 15;94(8):683-91 [17131422.001]
  • [Cites] Ann Ital Chir. 2006 Mar-Apr;77(2):107-13 [17147082.001]
  • [Cites] Head Neck. 1996 Mar-Apr;18(2):127-32 [8647677.001]
  • (PMID = 20463835.001).
  • [ISSN] 1827-675X
  • [Journal-full-title] Acta otorhinolaryngologica Italica : organo ufficiale della Società italiana di otorinolaringologia e chirurgia cervico-facciale
  • [ISO-abbreviation] Acta Otorhinolaryngol Ital
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2868202
  • [Keywords] NOTNLM ; Extra-capsular spread / Nodal metastases / Thyroid carcinoma
  •  go-up   go-down


34. Varandas VM, Coelho SM, Soeiro AP, Coeli CM, Carvalho DP, Buescu A, Vaisman M: [Clinical repercussion of the 6th edition TNM staging system classification on differentiated thyroid carcinoma]. Arq Bras Endocrinol Metabol; 2007 Jul;51(5):825-31
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical repercussion of the 6th edition TNM staging system classification on differentiated thyroid carcinoma].
  • The TNM classification of UICC is used for predicting the outcome of thyroid cancer.
  • Sixty-nine patients had papillary carcinoma, 14 follicular, 4 Hürthle cell, and 3 mixed.
  • For the stage IV there was a significant change in remission, however there was no difference comparing IV and IV C.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Carcinoma, Papillary / pathology. Thyroid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17891247.001).
  • [ISSN] 0004-2730
  • [Journal-full-title] Arquivos brasileiros de endocrinologia e metabologia
  • [ISO-abbreviation] Arq Bras Endocrinol Metabol
  • [Language] por
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


35. Weber F, Aldred MA, Morrison CD, Plass C, Frilling A, Broelsch CE, Waite KA, Eng C: Silencing of the maternally imprinted tumor suppressor ARHI contributes to follicular thyroid carcinogenesis. J Clin Endocrinol Metab; 2005 Feb;90(2):1149-55
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Silencing of the maternally imprinted tumor suppressor ARHI contributes to follicular thyroid carcinogenesis.
  • The two most common subtypes of thyroid cancer, follicular thyroid carcinoma (FTC) and papillary thyroid carcinoma, have been extensively studied, but our fundamental understanding of the molecular events in thyroid epithelial oncogenesis is still limited.
  • In this study, we elucidated the frequency and mechanism of ARHI silencing in benign and malignant thyroid neoplasia.
  • We demonstrated that underexpression of ARHI occurs principally in FTCs (P = 0.0018), including its oncocytic variant (11 of 13), even at minimally invasive stage but not classic papillary thyroid carcinoma (two of seven) or follicular adenoma (FA) (three of 14).
  • Therefore, our data suggest that silencing of the putative maternally imprinted tumor suppressor gene ARHI, primarily by large genomic deletion in conjunction with hypermethylation of the genomically imprinted allele, serves as a key early event in follicular thyroid carcinogenesis.
  • [MeSH-major] Azacitidine / analogs & derivatives. Gene Silencing. Genes, Tumor Suppressor. Genomic Imprinting / genetics. Thyroid Neoplasms / genetics. rho GTP-Binding Proteins / genetics
  • [MeSH-minor] Adenocarcinoma, Follicular / genetics. Adenocarcinoma, Follicular / pathology. Adenoma / genetics. Adenoma / pathology. Antimetabolites, Antineoplastic / pharmacology. Base Sequence. DNA Primers. Female. Gene Expression Regulation, Neoplastic / drug effects. Humans. Loss of Heterozygosity. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15546898.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA16059
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / DIRAS3 protein, human; 0 / DNA Primers; 776B62CQ27 / decitabine; EC 3.6.5.2 / rho GTP-Binding Proteins; M801H13NRU / Azacitidine
  •  go-up   go-down


36. Reschini E, Ferrari C, Castellani M, Matheoud R, Paracchi A, Marotta G, Gerundini P: The trapping-only nodules of the thyroid gland: prevalence study. Thyroid; 2006 Aug;16(8):757-62
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The trapping-only nodules of the thyroid gland: prevalence study.
  • The aim of this study was to determine the prevalence of trapping-only nodules of the thyroid gland.
  • The study was prospectively performed in patients bearing hot or warm thyroid nodules at pertechnetate scan in the presence of circulating thyrotropin (TSH) within the normal range.
  • Five had benign thyroid nodules, one follicular carcinoma, and one extrathyroid metastases of papillary-follicular carcinoma.
  • Despite controversy on this issue, trapping-only nodules of thyroid should be searched because they have risk of malignancy and must be differentiated from autonomous adenomas at the compensated stage.
  • [MeSH-major] Adenocarcinoma, Follicular / radionuclide imaging. Carcinoma / radionuclide imaging. Thyroid Neoplasms / radionuclide imaging. Thyroid Nodule / epidemiology. Thyroid Nodule / therapy. Thyrotropin / blood

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16910877.001).
  • [ISSN] 1557-9077
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 0 / Radiopharmaceuticals; 9002-71-5 / Thyrotropin; A0730CX801 / Sodium Pertechnetate Tc 99m
  •  go-up   go-down


37. Ito Y, Yoshida H, Tomoda C, Uruno T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Kuma K, Miyauchi A: Telomerase activity in thyroid neoplasms evaluated by the expression of human telomerase reverse transcriptase (hTERT). Anticancer Res; 2005 Jan-Feb;25(1B):509-14
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Telomerase activity in thyroid neoplasms evaluated by the expression of human telomerase reverse transcriptase (hTERT).
  • In this study, we studied teromerase activity in thyroid tumors using this antibody.
  • MATERIALS AND METHODS: We immunohistochemically investigated hTERT expression in 166 thyroid neoplasms.
  • In papillary carcinoma, high hTERT expression was observed in 34.5% of cases and it was directly linked to stage and the presence of lymph node metastasis.
  • In follicular carcinoma, 39.2% were classified as the high hTERT expression group, showing a significantly higher incidence than that in follicular adenoma, 9.8%.
  • In anaplastic carcinoma, 73.7% were regarded as the high hTERT expression group, which was larger than the percentages in papillary and follicular carcinomas.
  • We investigated the diagnostic usefulness of hTERT measurement for discriminating follicular carcinoma from adenoma.
  • CONCLUSION: These results suggest that: i) telomerase activity contributes to anaplastic transformation of differentiated carcinoma and ii) hTERT measurement may contribute to diagnosing follicular carcinoma, but whether it can be applied to preoperative diagnosis by fine-needle aspiration biopsy specimens remains unclear.
  • [MeSH-major] Telomerase / biosynthesis. Telomerase / metabolism. Thyroid Neoplasms / enzymology
  • [MeSH-minor] Adenocarcinoma, Follicular / metabolism. Adenoma / metabolism. Biopsy, Fine-Needle. Carcinoma, Papillary / metabolism. Cell Differentiation. DNA-Binding Proteins. Humans. Immunohistochemistry. Lymphatic Metastasis. RNA, Messenger / metabolism. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15816620.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / RNA, Messenger; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


38. Stepien T, Krupinski R, Sopinski J, Kuzdak K, Komorowski J, Lawnicka H, Stepien H: Decreased 1-25 dihydroxyvitamin D3 concentration in peripheral blood serum of patients with thyroid cancer. Arch Med Res; 2010 Apr;41(3):190-4
Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decreased 1-25 dihydroxyvitamin D3 concentration in peripheral blood serum of patients with thyroid cancer.
  • BACKGROUND AND AIMS: Vitamin D(3), in addition to its role in calcium homeostasis, has been recognized as playing a role in human cancer development.
  • However, little is known about the association between vitamin D status and the development of thyroid cancer.
  • This study aimed to investigate vitamin D metabolism by measuring 25(OH) D(3), 1-25 (OH)(2) D(3), PTH and calcium concentrations in the peripheral blood of patients with different forms of thyroid tumors.
  • METHODS: The 25-hydroxyvitamin D(3) ,1-25- dihydoxyvitamin D(3), PTH and calcium serum levels of 50 consecutive patients with epithelial thyroid cancer 27 cases of papillary cancers (PTC), 16 follicular cancers (FTC), and seven cases of anaplastic cancers (ATC) and 34 multinodular nontoxic goiter (MNG) were measured by specific immunoassay.
  • Levels of 1-25 (OH)(2) D(3) varied by cancer stage and were also significantly different.
  • A significant decrease in circulating 1-25 (OH)(2) D(3) concentration was found in patients with stage I (24.12 pg/mL +/- 6.77; p <0.05), stage II (16.93 pg/mL +/- 4.55; p <0.05), stage III (12.44 +/- 8.98; p <0.02) and in stage IVa (6.18 +/- 2.22; p <0.01).
  • There were no significant differences when comparing serum levels of 25(OH) D(3), PTH or calcium concentrations among individuals with multinodular goiter, thyroid cancer and age- and sex-matched control volunteers.
  • CONCLUSIONS: Our study revealed that impaired vitamin D(3) metabolism may play an important role in thyroid follicular cell oncogenesis.
  • [MeSH-major] Calcitriol / blood. Thyroid Neoplasms / blood
  • [MeSH-minor] Adenocarcinoma, Follicular / blood. Adenocarcinoma, Papillary / blood. Adult. Aged. Calcifediol / blood. Calcium / blood. Carcinoma, Papillary, Follicular / blood. Case-Control Studies. Female. Humans. Male. Middle Aged. Parathyroid Hormone / blood

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. 1,25-DIHYDROXYCHOLECALCIFEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 IMSS. Published by Elsevier Inc. All rights reserved.
  • [CommentIn] Arch Med Res. 2010 Jul;41(5):392; author reply 393 [20851300.001]
  • (PMID = 20682176.001).
  • [ISSN] 1873-5487
  • [Journal-full-title] Archives of medical research
  • [ISO-abbreviation] Arch. Med. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Parathyroid Hormone; FXC9231JVH / Calcitriol; P6YZ13C99Q / Calcifediol; SY7Q814VUP / Calcium
  •  go-up   go-down


39. Niedźwiecki S, Stepień T, Kuzdak K, Stepień H, Krupiński R, Seehofer D, Rayes N, Ulrich F: Serum levels of interleukin-1 receptor antagonist (IL-1ra) in thyroid cancer patients. Langenbecks Arch Surg; 2008 May;393(3):275-80
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum levels of interleukin-1 receptor antagonist (IL-1ra) in thyroid cancer patients.
  • Therefore, we performed a prospective study, analyzing IL-1ra in thyroid cancer patients.
  • MATERIALS AND METHODS: We measured preoperative IL-1ra serum levels of 52 consecutive patients with thyroid cancer, 15 with benign adenoma and 27 healthy volunteers.
  • The final histological diagnosis revealed 21 patients with papillary and 8 patients with follicular carcinoma (FTC), while 12 cases of medullary and 11 cases of anaplastic carcinoma (ATC) were observed.
  • Except for the stage IV disease in ATC, there was no correlation between IL-1ra levels and International Union Against Cancer staging.
  • Future efforts should focus on the possible application of IL-1ra as a biomarker for the above-mentioned thyroid malignancies.

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Langenbecks Arch Surg. 2009 Mar;394(2):401-2; author reply 403 [18825404.001]
  • (PMID = 18064485.001).
  • [ISSN] 1435-2451
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / IL1RN protein, human; 0 / Interleukin 1 Receptor Antagonist Protein
  •  go-up   go-down


40. Malterling RR, Andersson RE, Falkmer S, Falkmer U, Niléhn E, Järhult J: Differentiated thyroid cancer in a Swedish county--long-term results and quality of life. Acta Oncol; 2010 May;49(4):454-9
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differentiated thyroid cancer in a Swedish county--long-term results and quality of life.
  • BACKGROUND: There is still no complete agreement about the proper treatment of differentiated thyroid cancer (DTC).
  • Thirty nine patients had papillary cancers incidentally detected during surgery for benign disorders (median size 7 (1-30) mm).
  • Fifteen patients (12%) died from DTC but only one within stage I-II (1.2%).
  • Only three of 29 patients with isolated loco-regional spreading of their disease at the time of diagnosis have died from thyroid cancer.
  • There was no statistically significant difference in the 10 year cancer-specific survival rate between those operated with subtotal or total thyroidectomy--irrespective of stage.
  • Survival rate was significantly better for papillary than for follicular cancer.
  • CONCLUSIONS: Patients with DTC stage I-II (according to TNM) or low-risk (according to AMES) have an excellent prognosis.
  • [MeSH-major] Carcinoma / epidemiology. Carcinoma / surgery. Iodine Radioisotopes / therapeutic use. Quality of Life. Thyroid Neoplasms / epidemiology. Thyroid Neoplasms / surgery. Thyroidectomy / methods
  • [MeSH-minor] Adenocarcinoma, Follicular / epidemiology. Adenocarcinoma, Follicular / surgery. Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Papillary / epidemiology. Carcinoma, Papillary / surgery. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Prognosis. Radiotherapy, Adjuvant. Registries. Sample Size. Sweden / epidemiology. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20092427.001).
  • [ISSN] 1651-226X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Iodine Radioisotopes
  •  go-up   go-down


41. Schwartz DL, Lobo MJ, Ang KK, Morrison WH, Rosenthal DI, Ahamad A, Evans DB, Clayman G, Sherman SI, Garden AS: Postoperative external beam radiotherapy for differentiated thyroid cancer: outcomes and morbidity with conformal treatment. Int J Radiat Oncol Biol Phys; 2009 Jul 15;74(4):1083-91
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postoperative external beam radiotherapy for differentiated thyroid cancer: outcomes and morbidity with conformal treatment.
  • PURPOSE: To review institutional outcomes for patients treated for differentiated thyroid cancer with postoperative conformal external beam radiotherapy (EBRT).
  • METHODS AND MATERIALS: This is a single-institution retrospective review of 131 consecutive patients with differentiated thyroid cancer who underwent EBRT between January 1996 and December 2005.
  • Histologic diagnoses included 104 papillary, 21 follicular, and six mixed papillary-follicular types.
  • American Joint Committee on Cancer stage distribution was Stage III in 2 patients, Stage IVa-IVc in 128, and not assessable in 1.
  • CONCLUSIONS: Postoperative conformal EBRT provides durable locoregional disease control for patients with high-risk differentiated thyroid cancer if disease is reduced to microscopic burden.

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1985 May 1;55(9 Suppl):2062-71 [3919920.001]
  • [Cites] Am J Med. 1987 Sep;83(3):479-88 [3661584.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Jun;14(6):1063-75 [2454902.001]
  • [Cites] Head Neck Surg. 1987 Nov-Dec;10(2):107-12 [3507418.001]
  • [Cites] Otolaryngol Head Neck Surg. 1990 Jan;102(1):51-65 [2106118.001]
  • [Cites] Cancer. 1990 Apr 1;65(7):1517-20 [2311063.001]
  • [Cites] J Clin Endocrinol Metab. 1992 Sep;75(3):714-20 [1517360.001]
  • [Cites] Am J Surg. 1992 Dec;164(6):671-6 [1463122.001]
  • [Cites] Eur J Surg Oncol. 1993 Oct;19(5):399-404 [8405474.001]
  • [Cites] Oncology. 1994 Jul-Aug;51(4):372-9 [8208524.001]
  • [Cites] Eur J Cancer. 1994;30A(6):733-9 [7917529.001]
  • [Cites] Cancer. 1996 Jan 1;77(1):172-80 [8630926.001]
  • [Cites] Cancer. 1996 Aug 1;78(3):493-501 [8697396.001]
  • [Cites] Cancer. 1998 Jan 15;82(2):375-88 [9445196.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1419-26 [16154712.001]
  • [Cites] Am J Otolaryngol. 2006 Jan-Feb;27(1):24-8 [16360819.001]
  • [Cites] Endocr Relat Cancer. 2006 Dec;13(4):971-7 [17158749.001]
  • [Cites] Endocr Relat Cancer. 2006 Dec;13(4):1159-72 [17158761.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Mar 15;55(4):1006-12 [12605980.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2003 Sep;15(6):337-41 [14524487.001]
  • [Cites] Am J Roentgenol Radium Ther Nucl Med. 1966 Aug;97(4):923-30 [5953038.001]
  • [Cites] Ann Radiol (Paris). 1977 Nov-Dec;20(8):791-800 [416742.001]
  • [Cites] Radiology. 1980 Sep;136(3):753-6 [6773105.001]
  • [Cites] Am J Med. 1981 Mar;70(3):511-8 [7211893.001]
  • [Cites] Radiother Oncol. 2007 Oct;85(1):58-63 [17904235.001]
  • [Cites] Ann Surg Oncol. 2008 Jan;15(1):286-92 [17882493.001]
  • (PMID = 19095376.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA006294-43; United States / NCI NIH HHS / CA / P01 CA006294; United States / NCI NIH HHS / CA / P01 CA006294-43; United States / NCI NIH HHS / CA / P01 CA06294
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS128137; NLM/ PMC2745400
  •  go-up   go-down


42. Jonklaas J, Sarlis NJ, Litofsky D, Ain KB, Bigos ST, Brierley JD, Cooper DS, Haugen BR, Ladenson PW, Magner J, Robbins J, Ross DS, Skarulis M, Maxon HR, Sherman SI: Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid; 2006 Dec;16(12):1229-42
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of patients with differentiated thyroid carcinoma following initial therapy.
  • This analysis was performed to determine the effect of initial therapy on the outcomes of thyroid cancer patients.
  • Treatments employed included near-total thyroidectomy, administration of radioactive iodine, and thyroid hormone suppression therapy.
  • Near-total thyroidectomy, radioactive iodine, and aggressive thyroid hormone suppression therapy were each independently associated with longer overall survival in high-risk patients.
  • Near-total thyroidectomy followed by radioactive iodine therapy, and moderate thyroid hormone suppression therapy, both predicted improved overall survival in stage II patients.
  • No treatment modality, including lack of radioactive iodine, was associated with altered survival in stage I patients.
  • We also conclude that radioactive iodine therapy is beneficial for stage II, III, and IV patients.
  • Importantly, we show for the first time that superior outcomes are associated with aggressive thyroid hormone suppression therapy in high-risk patients, but are achieved with modest suppression in stage II patients.
  • We were unable to show any impact, positive or negative, of specific therapies in stage I patients.
  • [MeSH-major] Carcinoma, Papillary / therapy. Thyroid Neoplasms / therapy
  • [MeSH-minor] Adenocarcinoma, Follicular / therapy. Adult. Antithyroid Agents / therapeutic use. Cohort Studies. Female. Humans. Iodine Radioisotopes / therapeutic use. Male. Middle Aged. Neoplasm Staging. Prospective Studies. Registries. Risk. Survival Analysis. Thyroidectomy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Thyroid. 2007 Jun;17(6):595-6; author reply 596-7 [17614785.001]
  • (PMID = 17199433.001).
  • [ISSN] 1050-7256
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / K23 RR16524
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antithyroid Agents; 0 / Iodine Radioisotopes
  •  go-up   go-down


43. Lin JD, Chao TC: Follicular thyroid carcinoma: From diagnosis to treatment. Endocr J; 2006 Aug;53(4):441-8
SciCrunch. KEGG: Data: Disease Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follicular thyroid carcinoma: From diagnosis to treatment.
  • Unusual presentations with bone, lung or soft tissue metastases in initial diagnosis of follicular thyroid carcinoma have been reported occasionally.
  • This implies how difficult it is to diagnosis this type of cancer at the pre-operative or intra-operative stage of treatment.
  • Fine needle aspiration cytology has been shown to be an ineffective method for diagnosing vascular or capsule invasion of follicular thyroid cancer.
  • Clinical application of various gene expressions in thyroid follicular tumors by needle aspiration using in situ hybridization requires further investigation.
  • Although radioactive iodide (131I) has been used as the standard treatment for follicular thyroid carcinoma with distant metastases, the effectiveness of 131I treatment for follicular thyroid carcinoma depends on the differentiation of cancer cells.
  • The possibility of 131I for thyroid remnant ablation replacing a secondary operation for follicular thyroid carcinoma has been debated.
  • Recent studies applied more expressions of sodium iodide symporters to attain the effect of 131I treatment and slow the proliferation of thyroid cancer cell which, in turn, slows the progression of follicular carcinoma.
  • Consensus for the surgical procedures for the specific prognostic risks for follicular thyroid carcinoma is needed.
  • Dedifferentiated, anti-angiogenic, or gene therapies for follicular thyroid cancer with distant metastases or anaplastic transformation comprise the principal directions in future research for this cancer.
  • [MeSH-major] Adenocarcinoma, Follicular / diagnosis. Adenocarcinoma, Follicular / therapy. Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / therapy
  • [MeSH-minor] Biomarkers, Tumor / analysis. Biopsy, Fine-Needle. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / pathology. Carcinoma, Papillary / therapy. Diagnostic Imaging. Humans. Iodine Radioisotopes / therapeutic use. Predictive Value of Tests. Thyroidectomy

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16807500.001).
  • [ISSN] 0918-8959
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Iodine Radioisotopes
  • [Number-of-references] 72
  •  go-up   go-down


44. Eberhardt NL, Grebe SK, McIver B, Reddi HV: The role of the PAX8/PPARgamma fusion oncogene in the pathogenesis of follicular thyroid cancer. Mol Cell Endocrinol; 2010 May 28;321(1):50-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of the PAX8/PPARgamma fusion oncogene in the pathogenesis of follicular thyroid cancer.
  • When identified at early stages, most well-differentiated thyroid cancers are readily treated and yield excellent outcomes.
  • Follicular thyroid cancer (FTC) however, when diagnosed at a late stage, may be very resistant to treatment, and exhibits 10-year survival rates less than 40%.
  • Despite substantial progress in recent years, we still have limited understanding of the molecular and biological interrelationships between the various subtypes of benign and malignant follicular thyroid neoplasms.
  • In contrast to the wealth of information available regarding papillary thyroid carcinoma (PTC), the triggering mechanisms of FTC development and the major underlying genetic alterations leading to follicular thyroid carcinogenesis remain obscure.
  • Recent studies have focused on a chromosomal translocation, t(2;3) (q13;p25), fusing PAX8, a transcription factor that is essential for normal thyroid gland development, with the peroxisome proliferator-activated receptor gamma (PPARgamma), a member of the steroid/thyroid nuclear receptor family.

  • Genetic Alliance. consumer health - Thyroid cancer, follicular.
  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
  • [Cites] Thyroid. 2006 Nov;16(11):1091-6 [17123335.001]
  • [Cites] Pharmacol Rev. 2006 Dec;58(4):726-41 [17132851.001]
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1161-70 [17317825.001]
  • [Cites] Thyroid. 2007 Jun;17(6):497-509 [17614769.001]
  • [Cites] Curr Mol Med. 2007 Sep;7(6):532-40 [17896990.001]
  • [Cites] Clin Endocrinol (Oxf). 2007 Nov;67(5):706-11 [17651453.001]
  • [Cites] Cell Cycle. 2007 Nov 15;6(22):2817-25 [18032931.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Jan;93(1):278-84 [17989125.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Nov;265(1):265-71 [10548525.001]
  • [Cites] CA Cancer J Clin. 2000 Jan-Feb;50(1):7-33 [10735013.001]
  • [Cites] Science. 2000 Aug 25;289(5483):1357-60 [10958784.001]
  • [Cites] Science. 2000 Oct 6;290(5489):138-41 [11021799.001]
  • [Cites] Cancer J. 2000 Mar-Apr;6(2):50-7 [11069217.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 21;97(24):13144-9 [11069301.001]
  • [Cites] Oncogene. 2000 Nov 20;19(49):5590-7 [11114739.001]
  • [Cites] Thyroid. 2001 Apr;11(4):339-51 [11349832.001]
  • [Cites] Nutr Metab Cardiovasc Dis. 2001 Feb;11(1):64-9 [11383325.001]
  • [Cites] J Mol Endocrinol. 2001 Aug;27(1):1-9 [11463572.001]
  • [Cites] Cancer Res. 2001 Aug 15;61(16):6105-11 [11507060.001]
  • [Cites] Adv Anat Pathol. 2001 Nov;8(6):345-54 [11707626.001]
  • [Cites] J Biol Chem. 2001 Dec 21;276(51):48572-9 [11679588.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Aug;87(8):3947-52 [12161538.001]
  • [Cites] Am J Surg Pathol. 2002 Aug;26(8):1016-23 [12170088.001]
  • [Cites] Am J Pathol. 2003 Apr;162(4):1053-60 [12651598.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1454-7 [12670889.001]
  • [Cites] J Clin Endocrinol Metab. 2003 May;88(5):2318-26 [12727991.001]
  • [Cites] Oncogene. 2003 Jul 10;22(28):4406-12 [12853977.001]
  • [Cites] Am J Clin Pathol. 2003 Jul;120(1):71-7 [12866375.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Nov;88(11):5399-404 [14602780.001]
  • [Cites] Oncogene. 2004 Apr 29;23(20):3634-41 [15077183.001]
  • [Cites] Endocrinology. 1996 Jan;137(1):375-8 [8536638.001]
  • [Cites] Endocrinol Metab Clin North Am. 1995 Dec;24(4):761-801 [8608779.001]
  • [Cites] Surg Oncol Clin N Am. 1996 Jan;5(1):43-63 [8789493.001]
  • [Cites] Curr Opin Lipidol. 1997 Jun;8(3):159-66 [9211064.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Nov;82(11):3684-91 [9360526.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Feb;83(2):525-30 [9467569.001]
  • [Cites] Nat Genet. 1998 May;19(1):83-6 [9590296.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5523-8 [9850089.001]
  • [Cites] Recent Results Cancer Res. 1998;154:265-70 [10027006.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Oct 14;264(1):93-9 [10527847.001]
  • [Cites] Curr Med Chem Anticancer Agents. 2004 Nov;4(6):465-77 [15579013.001]
  • [Cites] J Clin Invest. 2005 Apr;115(4):1068-81 [15761501.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4238-45 [15899815.001]
  • [Cites] Cancer Causes Control. 2005 Apr;16(3):309-20 [15947883.001]
  • [Cites] Thyroid. 2005 Jun;15(6):594-9 [16029127.001]
  • [Cites] Endocrinology. 2005 Oct;146(10):4456-63 [16002527.001]
  • [Cites] Endocrinology. 2006 Jan;147(1):367-76 [16179407.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jan;91(1):213-20 [16219715.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Mar;91(3):1143-9 [16352687.001]
  • [Cites] Crit Rev Oncol Hematol. 2006 Apr;58(1):1-14 [16388966.001]
  • [Cites] Clin Cancer Res. 2006 Mar 15;12(6):1785-93 [16551863.001]
  • [Cites] Oncogene. 2006 Apr 13;25(16):2304-17 [16331265.001]
  • [Cites] JAMA. 2006 May 10;295(18):2164-7 [16684987.001]
  • [Cites] Endocr Relat Cancer. 2006 Jun;13(2):485-95 [16728576.001]
  • [Cites] Ann N Y Acad Sci. 2006 Sep;1076:29-53 [17119192.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Endocrinol Metab Clin North Am. 2008 Jun;37(2):375-87, viii-ix [18502332.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Jun;93(6):2194-201 [18381570.001]
  • [Cites] Cancer Res. 2008 Aug 15;68(16):6578-86 [18701481.001]
  • [Cites] Cancer Res. 2008 Sep 1;68(17):7156-64 [18757431.001]
  • [Cites] Hum Pathol. 2008 Oct;39(10):1540-7 [18602667.001]
  • [Cites] Cancer Res. 2009 Jan 15;69(2):687-94 [19147585.001]
  • [Cites] Endocr Metab Immune Disord Drug Targets. 2009 Mar;9(1):76-83 [19275683.001]
  • [Cites] Hum Pathol. 2009 Jun;40(6):827-33 [19200582.001]
  • (PMID = 19883731.001).
  • [ISSN] 1872-8057
  • [Journal-full-title] Molecular and cellular endocrinology
  • [ISO-abbreviation] Mol. Cell. Endocrinol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA080117-08; United States / NCI NIH HHS / CA / R01 CA080117-08
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion; 0 / PAX8-PPARgamma fusion protein, human; 0 / PPAR gamma; 0 / Paired Box Transcription Factors
  • [Number-of-references] 85
  • [Other-IDs] NLM/ NIHMS161308; NLM/ PMC2849860
  •  go-up   go-down


45. Lind P, Kohlfürst S: Respective roles of thyroglobulin, radioiodine imaging, and positron emission tomography in the assessment of thyroid cancer. Semin Nucl Med; 2006 Jul;36(3):194-205
Hazardous Substances Data Bank. THYROGLOBULIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Respective roles of thyroglobulin, radioiodine imaging, and positron emission tomography in the assessment of thyroid cancer.
  • Depending on the iodine supply of an area, the incidence of thyroid cancer ranges between 4 and 12/100,000 per year.
  • To detect thyroid cancer in an early stage, the assessment of thyroid nodules includes ultrasonography, ultrasonography-guided fine-needle aspiration biopsy, and conventional scintigraphic methods using (99m)Tc-pertechnetate, (99m)Tc-sestamibi or -tetrofosmin, and (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) in selected cases.
  • After treatment of thyroid cancer, a consequent follow-up is necessary over a period of several years.
  • For following up low-risk patients, recombinant thyroid-stimulating hormone-stimulated thyroglobulin and ultrasonography is sufficient in most cases.
  • After total thyroidectomy and radioiodine ablation therapy, thyroid-stimulating hormone-stimulated thyroglobulin should be below the detection limit (eg, <0.5 ng/mL, R: 70-130).
  • In patients with low or dedifferentiated thyroid cancer and after several courses of radioiodine therapy caused by metastatic disease, iodine negative metastases may develop.
  • [MeSH-major] Adenocarcinoma, Follicular / radionuclide imaging. Carcinoma, Papillary / radionuclide imaging. Fluorodeoxyglucose F18. Iodine Radioisotopes. Positron-Emission Tomography. Radiopharmaceuticals. Thyroglobulin / blood. Thyroid Neoplasms / radionuclide imaging
  • [MeSH-minor] Biomarkers, Tumor / blood. Biopsy, Fine-Needle. Follow-Up Studies. Humans. Liver Neoplasms / radionuclide imaging. Liver Neoplasms / secondary. Lung Neoplasms / radionuclide imaging. Lung Neoplasms / secondary. Lymphatic Metastasis / radionuclide imaging. Neoplasm Recurrence, Local / radionuclide imaging. Preoperative Care. Radiometry / methods. Sensitivity and Specificity. Thyroid Nodule / pathology. Thyroid Nodule / radionuclide imaging. Thyroid Nodule / ultrasonography. Thyrotropin. Tomography, Emission-Computed, Single-Photon. Tomography, X-Ray Computed / methods

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16762610.001).
  • [ISSN] 0001-2998
  • [Journal-full-title] Seminars in nuclear medicine
  • [ISO-abbreviation] Semin Nucl Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Iodine Radioisotopes; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 9002-71-5 / Thyrotropin; 9010-34-8 / Thyroglobulin
  • [Number-of-references] 82
  •  go-up   go-down


46. Lundgren CI, Hall P, Dickman PW, Zedenius J: Clinically significant prognostic factors for differentiated thyroid carcinoma: a population-based, nested case-control study. Cancer; 2006 Feb 1;106(3):524-31
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinically significant prognostic factors for differentiated thyroid carcinoma: a population-based, nested case-control study.
  • BACKGROUND: Different scoring systems currently are being used to stratify patients with differentiated thyroid carcinoma (DTC) into risk groups.
  • DTC is usually subdivided into papillary thyroid carcinoma (PTC) and follicular thyroid carcinoma (FTC).
  • Patients with TNM Stage IV disease had a higher mortality rate compared with patients with Stage II disease (odds ratio [OR]=9.1; 95% confidence interval [95% CI], 5.7-14.6).
  • Incomplete surgical excision was associated with higher mortality, particularly in patients with Stage I disease.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Carcinoma, Papillary / pathology. Neoplasm Staging / standards. Thyroid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 American Cancer Society.
  • (PMID = 16369995.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


47. Bhargav PR, Mishra A, Agarwal G, Agarwal A, Pradhan PK, Gambhir S, Verma AK, Mishra SK: Long-term outcome of differentiated thyroid carcinoma: experience in a developing country. World J Surg; 2010 Jan;34(1):40-7
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome of differentiated thyroid carcinoma: experience in a developing country.
  • BACKGROUND: The presentation and outcome of differentiated thyroid carcinoma (DTC) in developing countries are different from the developed nations.
  • Papillary thyroid carcinoma (PTC), follicular thyroid carcinoma (FTC), and poorly differentiated thyroid carcinoma (PDTC) was present in 62, 30, and 8% patients, respectively.
  • Disease recurred in 26.6% of patients (thyroid bed recurrence 1.7%), and 21.2% patients died during follow-up.
  • CONCLUSIONS: Advance stage at presentation and proportionately high rates of FTC and PDTC contribute to poor outcome of DTC in developing countries.
  • Despite dismal outcome, total thyroidectomy seems to prevent thyroid bed recurrence in surviving patients.
  • [MeSH-major] Thyroid Neoplasms / pathology. Thyroid Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma, Follicular / pathology. Adenocarcinoma, Follicular / surgery. Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Papillary / pathology. Carcinoma, Papillary / surgery. Child. Developing Countries. Female. Follow-Up Studies. Humans. India / epidemiology. Linear Models. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Metastasis. Retrospective Studies. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20020292.001).
  • [ISSN] 1432-2323
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Kłubo-Gwieździńska J, Junik R: [The early treatment results of well differentiated thyroid cancer and its dependence on chosen factors]. Endokrynol Pol; 2008 Mar-Apr;59(2):123-30
Hazardous Substances Data Bank. THYROGLOBULIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The early treatment results of well differentiated thyroid cancer and its dependence on chosen factors].
  • INTRODUCTION: The aim of the study was to estimate the influence of a thyroid remnants' volume, postsurgical concentration of thyroglobulin and radioiodine dose on the early treatment efficacy of well differentiated thyroid cancer.
  • MATERIAL AND METHODS: We retrospectively analyzed 91 patients (76 females, 15 men) with well differentiated thyroid cancer.
  • RESULTS: Histological classification revealed 68.1% (62/91) papillary thyroid cancers, 25.3% (23/91) follicular thyroid cancers, and 6.6% (6/91) oxyphilic thyroid cancers.
  • The remission was obtained in 100% of patients in stage I of the disease, 68.4% - in stage II, 78.6% - in stage III and 33.3% in stage IV.
  • CONCLUSIONS: Early treatment results of well differentiated thyroid cancer depend on the clinical stage, and postoperative serum thyroglobulin level measured after endogenous TSH stimulation.
  • Early treatment results are not dependent on age, sex, histological type of thyroid cancer, the dose of radioiodine used in brackets of 60-150 mCi and additional diseases.
  • [MeSH-major] Adenocarcinoma, Follicular / therapy. Carcinoma, Papillary / therapy. Thyroid Neoplasms / therapy

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. LEVOTHYROXINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18465687.001).
  • [ISSN] 0423-104X
  • [Journal-full-title] Endokrynologia Polska
  • [ISO-abbreviation] Endokrynol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 9010-34-8 / Thyroglobulin; Q51BO43MG4 / Thyroxine
  •  go-up   go-down


49. Kloos RT, Ringel MD, Knopp MV, Hall NC, King M, Stevens R, Liang J, Wakely PE Jr, Vasko VV, Saji M, Rittenberry J, Wei L, Arbogast D, Collamore M, Wright JJ, Grever M, Shah MH: Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol; 2009 Apr 1;27(10):1675-84
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of sorafenib in metastatic thyroid cancer.
  • PURPOSE: Based on the pivotal role of Ras-Raf-MAP-ERK signaling and vascular endothelial growth factor (VEGF) in papillary thyroid cancer (PTC), we conducted a phase II clinical trial of sorafenib targeting RAF and VEGF receptor kinases in PTC.
  • Using a Simon minimax two-stage design, 16 or 25 chemotherapy-naïve metastatic PTC patients were to be enrolled in arm A (accessible tumor for biopsy).
  • Arm B patients had other subtypes of thyroid carcinoma or prior chemotherapy, and did not require tumor biopsies.


50. Pallante P, Federico A, Berlingieri MT, Bianco M, Ferraro A, Forzati F, Iaccarino A, Russo M, Pierantoni GM, Leone V, Sacchetti S, Troncone G, Santoro M, Fusco A: Loss of the CBX7 gene expression correlates with a highly malignant phenotype in thyroid cancer. Cancer Res; 2008 Aug 15;68(16):6770-8
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of the CBX7 gene expression correlates with a highly malignant phenotype in thyroid cancer.
  • Using gene expression profiling, we found that the CBX7 gene was drastically down-regulated in six thyroid carcinoma cell lines versus control cells.
  • The aims of this study were to determine whether CBX7 is related to the thyroid cancer phenotype and to try to identify new tools for the diagnosis and prognosis of thyroid cancer.
  • We thus evaluated CBX7 expression in various snap-frozen and paraffin-embedded thyroid carcinoma tissues of different degrees of malignancy by quantitative reverse transcription-PCR and immunohistochemistry, respectively.
  • CBX7 expression progressively decreased with malignancy grade and neoplasia stage.
  • Indeed, it decreased in an increasing percentage of cases going from benign adenomas to papillary (PTC), follicular, and anaplastic (ATC) thyroid carcinomas.
  • This finding coincides with results obtained in rat and mouse models of thyroid carcinogenesis.
  • Restoration of CBX7 expression in thyroid cancer cells reduced growth rate, with a retention in the G(1) phase of the cell cycle, suggesting that CBX7 can contribute to the proliferation of the transformed thyroid cells.
  • In conclusion, loss of CBX7 expression correlates with a highly malignant phenotype in thyroid cancer patients.
  • [MeSH-major] Adenocarcinoma, Follicular / genetics. Carcinoma / genetics. Carcinoma, Papillary / genetics. Repressor Proteins / genetics. Repressor Proteins / metabolism. Thyroid Neoplasms / genetics
  • [MeSH-minor] Adenoviridae / genetics. Animals. Blotting, Western. Cell Line, Tumor. Cell Proliferation. Chromosomes, Human, Pair 22 / genetics. Colony-Forming Units Assay. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Gene Expression Regulation, Neoplastic. Humans. Loss of Heterozygosity. Mice. Mice, Nude. Polycomb Repressive Complex 1. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Rats. Reverse Transcriptase Polymerase Chain Reaction. Thyroid Gland / metabolism. Thyroid Gland / pathology

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18701502.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CBX7 protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Repressor Proteins; EC 6.3.2.19 / Polycomb Repressive Complex 1
  •  go-up   go-down


51. Czarniecka A, Jarzab M, Krajewska J, Jurecka-Lubieniecka B, Paliczka E, Sacher A, Półtorak S, Włoch J: [Evaluation of the therapeutic benefits in relation to the extent of surgery in patients with differentiated thyroid carcinoma]. Endokrynol Pol; 2006 Jul-Aug;57(4):362-9
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Evaluation of the therapeutic benefits in relation to the extent of surgery in patients with differentiated thyroid carcinoma].
  • INTRODUCTION: Evaluation of the therapeutic benefits in relation to the stage of thyroid cancer and to the extent of surgery and the risk of postoperative complications.
  • MATERIAL AND METHODS: Retrospective analysis of differentiated thyroid carcinoma (DTC) patients staged T1M0 versus T2-T4M0 was performed.
  • It showed that total thyroidectomy brings a significant therapeutic benefits in patients in > T1M0 stage.
  • [MeSH-major] Adenocarcinoma, Follicular / surgery. Carcinoma, Papillary / surgery. Neoplasm Recurrence, Local / surgery. Neoplasm, Residual / surgery. Thyroid Neoplasms / surgery. Thyroidectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17006837.001).
  • [ISSN] 0423-104X
  • [Journal-full-title] Endokrynologia Polska
  • [ISO-abbreviation] Endokrynol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


52. Milas M, Barbosa GF, Mitchell J, Berber E, Siperstein A, Gupta M: Effectiveness of peripheral thyrotropin receptor mRNA in follow-up of differentiated thyroid cancer. Ann Surg Oncol; 2009 Feb;16(2):473-80
Hazardous Substances Data Bank. THYROGLOBULIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effectiveness of peripheral thyrotropin receptor mRNA in follow-up of differentiated thyroid cancer.
  • Thyroid cells in peripheral circulation have been linked to thyroid cancer (TC).
  • Thirty-four patients underwent 20 +/- 14 months median follow-up for papillary (n = 31, 91%), follicular (n = 2) or Hurthle cell (n = 1) TC.
  • Advanced-stage disease occurred in 24% at presentation, and 11 (32%) developed cervical node metastases or recurrence requiring reoperation during follow-up.
  • [MeSH-major] RNA, Messenger / blood. Receptors, Thyrotropin / genetics. Thyroid Neoplasms / blood
  • [MeSH-minor] Adenocarcinoma, Follicular / blood. Adenocarcinoma, Follicular / secondary. Adenocarcinoma, Follicular / surgery. Adenoma, Oxyphilic / blood. Adenoma, Oxyphilic / secondary. Adenoma, Oxyphilic / surgery. Adult. Aged. Autoantibodies / blood. Biomarkers, Tumor / blood. Carcinoma, Papillary / blood. Carcinoma, Papillary / secondary. Carcinoma, Papillary / surgery. Cell Differentiation. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local / blood. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / surgery. Positron-Emission Tomography. Prospective Studies. Reverse Transcriptase Polymerase Chain Reaction. Thyroglobulin / blood. Thyroglobulin / genetics. Thyroglobulin / immunology. Thyroidectomy. Thyrotropin / pharmacology. Young Adult

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19015922.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / Receptors, Thyrotropin; 9002-71-5 / Thyrotropin; 9010-34-8 / Thyroglobulin
  •  go-up   go-down


53. Santoro M, Carlomagno F: Drug insight: Small-molecule inhibitors of protein kinases in the treatment of thyroid cancer. Nat Clin Pract Endocrinol Metab; 2006 Jan;2(1):42-52
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Drug insight: Small-molecule inhibitors of protein kinases in the treatment of thyroid cancer.
  • Molecular targeting of protein kinases is a new paradigm in the treatment of cancer.
  • Thyroid cancer is the most prevalent endocrine malignancy and is frequently associated with the oncogenic conversion of two specific protein kinases, RET and BRAF.
  • Small-molecule inhibitors of both kinases have already reached the clinical testing stage.
  • Protein kinases other than RET and BRAF are also being evaluated for their potential in thyroid-cancer treatment.
  • [MeSH-major] Protein Kinase Inhibitors / therapeutic use. Thyroid Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma, Follicular / etiology. Carcinoma, Medullary / etiology. Carcinoma, Papillary / etiology. Gene Targeting. Humans. Models, Biological. Protein-Serine-Threonine Kinases / antagonists & inhibitors. Protein-Tyrosine Kinases / antagonists & inhibitors. Proto-Oncogene Proteins B-raf / genetics. Proto-Oncogene Proteins c-ret / genetics. RNA Interference

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16932252.001).
  • [ISSN] 1745-8366
  • [Journal-full-title] Nature clinical practice. Endocrinology & metabolism
  • [ISO-abbreviation] Nat Clin Pract Endocrinol Metab
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Proto-Oncogene Proteins c-ret; EC 2.7.10.1 / RET protein, human; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  • [Number-of-references] 73
  •  go-up   go-down


54. Pelttari H, Välimäki MJ, Löyttyniemi E, Schalin-Jäntti C: Post-ablative serum thyroglobulin is an independent predictor of recurrence in low-risk differentiated thyroid carcinoma: a 16-year follow-up study. Eur J Endocrinol; 2010 Nov;163(5):757-63
Hazardous Substances Data Bank. THYROGLOBULIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Post-ablative serum thyroglobulin is an independent predictor of recurrence in low-risk differentiated thyroid carcinoma: a 16-year follow-up study.
  • OBJECTIVE: To study whether post-surgical and/or post-ablative thyroglobulin (Tg) concentrations may serve as independent predictors of disease recurrence in patients treated for TNM stage I or II well-differentiated thyroid carcinoma (WDTC).
  • PATIENTS AND MEASUREMENTS: Post-operative and post-ablative Tg concentrations, age, tumour size, local infiltration and nodal metastasis at primary surgery as well as disease recurrences and cancer-specific deaths were evaluated in 495 low-risk (TNM stages I and II) patients, the majority of whom had total thyroidectomy and radioactive iodine remnant ablation as initial treatment.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20813788.001).
  • [ISSN] 1479-683X
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 9010-34-8 / Thyroglobulin
  •  go-up   go-down


55. Rivera M, Ricarte-Filho J, Patel S, Tuttle M, Shaha A, Shah JP, Fagin JA, Ghossein RA: Encapsulated thyroid tumors of follicular cell origin with high grade features (high mitotic rate/tumor necrosis): a clinicopathologic and molecular study. Hum Pathol; 2010 Feb;41(2):172-80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Encapsulated thyroid tumors of follicular cell origin with high grade features (high mitotic rate/tumor necrosis): a clinicopathologic and molecular study.
  • Encapsulated thyroid tumors of follicular cell origin with high-grade features (EFHG) are unusual neoplasms.
  • In current classification schemes, they are called atypical adenomas or follicular, papillary, or poorly differentiated carcinoma.
  • When noninvasive, EFHG create a major therapeutic/diagnostic dilemma stemming from their rarity, low-stage, high-grade appearance, and lack of long-term follow-up studies.
  • Available tissues were subjected to a thyroid carcinoma platform for mass spectrometry high-throughput genotyping, which consisted of 111 known mutations in 16 different genes: BRAF, RET, NRAS, HRAS, KRAS, PIK3CA, AKT1, and other related genes.
  • [MeSH-major] Adenocarcinoma, Follicular / genetics. Adenocarcinoma, Follicular / pathology. Thyroid Neoplasms / genetics. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 19913280.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA050706; United States / NCI NIH HHS / CA / R01 CA072597
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ NIHMS720096; NLM/ PMC4573458
  •  go-up   go-down


56. Tachihara-Yoshikawa M, Ishida T, Watanabe K, Sugawara A, Kanazawa K, Kanno R, Suzuki T, Niimi T, Kimura S, Munakata M: Expression of secretoglobin3A2 (SCGB3A2) in primary pulmonary carcinomas. Fukushima J Med Sci; 2008 Dec;54(2):61-72
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Secretoglobin (SCGB) 3A2 is a downstream target gene for the thyroid transcription factor-1 (TITF1).
  • The expression in papillary adenocarcinomas was seen at higher frequency than that in tubular adenocarcinomas.
  • There was no significant relationship between SCGB3A2 expression and tumor differentiation, and pathological stage.
  • [MeSH-major] Adenocarcinoma / chemistry. Carcinoma, Small Cell / chemistry. Carcinoma, Squamous Cell / chemistry. Lung Neoplasms / chemistry. Uteroglobin / analysis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Respir Crit Care Med. 2006 May 1;173(9):958-64 [16456148.001]
  • [Cites] J Biol Chem. 2004 Dec 24;279(52):54358-68 [15485815.001]
  • [Cites] Mod Pathol. 1999 Mar;12(3):318-24 [10102618.001]
  • [Cites] Ann N Y Acad Sci. 2000;923:193-201 [11193757.001]
  • [Cites] Ann N Y Acad Sci. 2000;923:234-48 [11193760.001]
  • [Cites] Ann N Y Acad Sci. 2000;923:249-67 [11193761.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9796-801 [11481438.001]
  • [Cites] Mol Endocrinol. 2001 Nov;15(11):2021-36 [11682631.001]
  • [Cites] Am J Hum Genet. 2002 Mar;70(3):718-25 [11813133.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2002 Jun;10(2):103-9 [12051626.001]
  • [Cites] Mech Dev. 2002 Jun;114(1-2):201-4 [12175512.001]
  • [Cites] Mod Pathol. 2002 Oct;15(10):1058-67 [12379752.001]
  • [Cites] Cytogenet Genome Res. 2002;97(1-2):120-7 [12438750.001]
  • [Cites] Am J Respir Crit Care Med. 2002 Dec 1;166(11):1498-509 [12406855.001]
  • [Cites] Hum Pathol. 2003 Jun;34(6):597-604 [12827614.001]
  • [Cites] J Immunol. 2003 Jul 15;171(2):924-30 [12847263.001]
  • [Cites] Int Arch Allergy Immunol. 2003 Aug;131(4):291-5 [12915772.001]
  • [Cites] Mol Cell Biol. 1994 Sep;14(9):5671-81 [8065304.001]
  • [Cites] J Biol Chem. 1995 Mar 24;270(12):6531-6 [7896788.001]
  • [Cites] Genes Dev. 1996 Jan 1;10(1):60-9 [8557195.001]
  • [Cites] Mol Cell Biol. 1996 May;16(5):2056-64 [8628271.001]
  • [Cites] J Biol Chem. 1996 Mar 22;271(12):6881-8 [8636114.001]
  • [Cites] Mod Pathol. 1996 Apr;9(4):445-52 [8729987.001]
  • [Cites] J Clin Pathol. 1997 Jan;50(1):30-2 [9059352.001]
  • [Cites] Cell Growth Differ. 1998 Jun;9(6):475-85 [9663466.001]
  • [Cites] J Neurooncol. 1998 Dec;40(3):227-31 [10066094.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2004 Dec;287(6):L1193-8 [15531759.001]
  • [Cites] Cancer Res. 2005 Nov 1;65(21):9659-69 [16266985.001]
  • [Cites] Immunol Lett. 2005 Feb 15;97(1):123-9 [15626484.001]
  • [Cites] Ann Oncol. 2006 Nov;17(11):1673-6 [16980598.001]
  • (PMID = 19418968.001).
  • [ISSN] 0016-2590
  • [Journal-full-title] Fukushima journal of medical science
  • [ISO-abbreviation] Fukushima J Med Sci
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 BC010449-06; United States / Intramural NIH HHS / / Z99 CA999999
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Nuclear Proteins; 0 / SCGB3A2 protein, human; 0 / Secretoglobins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1; 9060-09-7 / Uteroglobin
  • [Other-IDs] NLM/ NIHMS102164; NLM/ PMC2743607
  •  go-up   go-down


57. Enomoto K, Sakurai K, Amano S, Shiono M: [A case of advanced breast carcinoma with local hemorrhage during a control of hyperthyroidism]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2490-2
MedlinePlus Health Information. consumer health - Hyperthyroidism.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced breast carcinoma with local hemorrhage during a control of hyperthyroidism].
  • A medical check-up was done and diagnosed as T4b, N0, M0, stage IIIB of the breast cancer by a close inspection.
  • We waited for a thyroid function to be normalized.
  • In January 2009, we observed a bleeding from the part of the breast cancer.
  • We controlled the thyroid function by internal medicine.
  • Because we were able to control the hyperthyroidism this time and a thyroid function to be stabilized for a local advanced breast carcinoma with the hemorrhage temporarily, and were able to operate for the breast cancer, as we reported it in this study.
  • [MeSH-major] Breast Neoplasms / complications. Carcinoma, Ductal, Breast / complications. Hemorrhage / etiology. Hyperthyroidism / drug therapy
  • [MeSH-minor] Adenocarcinoma / complications. Adenocarcinoma / surgery. Carcinoma, Papillary / complications. Carcinoma, Papillary / surgery. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Bleeding.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037465.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


58. Kajiwara H, Kumaki N, Hirabayashi K, Miyazawa M, Nakamura N, Hirasawa T, Muramatsu T, Mikami M, Yasuda M, Osamura RY: A case of oncocytic carcinoma of the endometrium. Arch Gynecol Obstet; 2009 May;279(5):733-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of oncocytic carcinoma of the endometrium.
  • We report an unusual case of endometrial adenocarcinoma in a 80-year-old woman who underwent mastectomy for breast cancer at 68 years of age.
  • Atypical cells throughout the tumor contained abundant oxiphilic cytoplasm and were arranged in a solid or solid-tubular nests in a focal papillary manner.
  • Components of the carcinoma were focally observed in situ.
  • The tumor was classified according to the International Federation of Gynecology and Obstetrics (FIGO) as grade 2 and stage IIIa.
  • They were positive for antimitochondrial antigen and thyroid transcription factor-1.
  • Immunostaining revealed endometrial oncocytic carcinoma.
  • Distinguishing between primary uterine neoplasm and carcinoma caused by metastasis of breast cancer appears important.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Neoplasms, Second Primary / pathology

  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18795309.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


59. Solis LM, Raso MG, Kalhor N, Behrens C, Wistuba II, Moran CA: Primary oncocytic adenocarcinomas of the lung: a clinicopathologic, immunohistochemical, and molecular biologic analysis of 16 cases. Am J Clin Pathol; 2010 Jan;133(1):133-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Surgical staging disclosed 14 patients (88%) with stage I disease, 1 (6%) with stage II, and 1 (6%) with stage III.
  • Histologically, all the cases displayed prominent oncocytic features with conventional growth patterns, including acinar, papillary, and bronchioloalveolar.
  • Immunohistochemically, the tumors displayed positive staining for keratin 7, thyroid transcription factor-1, and mitochondrial antibody.
  • These cases represent an unusual variant of pulmonary adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Lung Neoplasms / pathology. Oxyphil Cells / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20023269.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Case Reports; Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


60. Bergmann F, Esposito I, Michalski CW, Herpel E, Friess H, Schirmacher P: Early undifferentiated pancreatic carcinoma with osteoclastlike giant cells: direct evidence for ductal evolution. Am J Surg Pathol; 2007 Dec;31(12):1919-25
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early undifferentiated pancreatic carcinoma with osteoclastlike giant cells: direct evidence for ductal evolution.
  • However, to date, early stage tumors have not been described, most likely because of the fact that at the time of diagnosis the tumors have commonly reached advanced stages with large tumor size.
  • In this report, we present the case of an undifferentiated pancreatic carcinoma with osteoclastlike giant cells, which was incidentally detected at a very early stage in a pancreatitis specimen.
  • Therefore, we suggest that the tumor should be considered as an anaplastic variant of pancreatic ductal adenocarcinoma.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / pathology. Giant Cells / pathology. Osteoclasts / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Papillary / pathology. Biomarkers, Tumor / analysis. Diabetes Mellitus, Type 2 / pathology. Female. Humans. Incidental Findings. Middle Aged. Neoplasms, Second Primary / metabolism. Neoplasms, Second Primary / pathology. Smoking. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18043049.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


61. Masciari S, Van den Abbeele AD, Diller LR, Rastarhuyeva I, Yap J, Schneider K, Digianni L, Li FP, Fraumeni JF Jr, Syngal S, Garber JE: F18-fluorodeoxyglucose-positron emission tomography/computed tomography screening in Li-Fraumeni syndrome. JAMA; 2008 Mar 19;299(11):1315-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONTEXT: Individuals with Li-Fraumeni syndrome (LFS) have an inherited cancer predisposition to a diverse array of malignancies beginning early in life; survivors of one cancer have a markedly elevated risk of additional primary tumors.
  • DESIGN, SETTING, AND PARTICIPANTS: Members of LFS families with documented germline TP53 mutations or obligate carrier status, no history of cancer within 5 years of enrollment, and no symptoms of cancer or ill-health were offered FDG-PET/CT scanning as a screening test in a comprehensive US cancer center from 2006 to 2007.
  • Two individuals had papillary thyroid cancers (stage II and stage III) and one individual had stage II esophageal adenocarcinoma.
  • CONCLUSIONS: These preliminary data provide the first evidence for a potential cancer surveillance strategy that may be worthy of further investigation for patients with LFS.

  • Genetic Alliance. consumer health - Li Fraumeni syndrome.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18349092.001).
  • [ISSN] 1538-3598
  • [Journal-full-title] JAMA
  • [ISO-abbreviation] JAMA
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


62. McKeon A, Apiwattanakul M, Lachance DH, Lennon VA, Mandrekar JN, Boeve BF, Mullan B, Mokri B, Britton JW, Drubach DA, Pittock SJ: Positron emission tomography-computed tomography in paraneoplastic neurologic disorders: systematic analysis and review. Arch Neurol; 2010 Mar;67(3):322-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To evaluate the cancer detection rate of whole-body positron emission tomography-computed tomography (PET-CT) in a paraneoplastic neurologic context.
  • MAIN OUTCOME MEASURE: Rate of cancer detection.
  • RESULTS: Abnormalities suggestive of cancer were detected using PET-CT in 22 patients (39%); 10 patients (18%) had cancer confirmed histologically.
  • Cancers detected (limited stage in 9 of 10 patients and extratruncal in 4) were as follows: 2 thyroid papillary cell carcinomas, 3 solitary lymph nodes with unknown primary (2 adenocarcinomas and 1 small cell carcinoma), 1 tonsil squamous cell carcinoma, 3 lung carcinomas (1 adenocarcinoma, 1 small cell, and 1 squamous cell), and 1 colon adenocarcinoma.
  • Detection of a well-characterized neuronal nuclear or cytoplasmic paraneoplastic autoantibody was associated with a successful PET-CT-directed cancer search (P < .001).
  • Detection of limited-stage cancer facilitated early initiation of oncologic treatments and immunotherapy; cancer remission was reported in 7 patients, and sustained improvements in neurologic symptoms were reported in 5 (median follow-up, 11 months; range, 2-48 months).
  • Combined data from 2 previous studies using conventional PET alone (123 patients) revealed that 28% of patients had a PET abnormality suggestive of cancer and that 12% had a cancer diagnosis.
  • CONCLUSION: In a paraneoplastic neurologic context, PET-CT improves the detection of cancers when other screening test results are negative, particularly in the setting of seropositivity for a neuronal nuclear or cytoplasmic autoantibody marker of cancer.
  • [MeSH-major] Early Detection of Cancer / methods. Neoplasms / diagnosis. Paraneoplastic Syndromes, Nervous System / diagnosis

  • Genetic Alliance. consumer health - Paraneoplastic Neurologic Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20065123.001).
  • [ISSN] 1538-3687
  • [Journal-full-title] Archives of neurology
  • [ISO-abbreviation] Arch. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Lachkhem A, Khamassi K, Touati S, Charrada K, Ben Miled M, Oueslati Z, El May A, Ben Slimène F, Gritli S: [Advantages of completion thyroidectomy as a second stage for differentiated thyroid cancer]. J Chir (Paris); 2009 Oct;146(5):520-1
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Advantages of completion thyroidectomy as a second stage for differentiated thyroid cancer].
  • [MeSH-major] Adenocarcinoma, Follicular / surgery. Carcinoma, Papillary / surgery. Carcinoma, Papillary, Follicular / surgery. Thyroid Neoplasms / surgery. Thyroid Nodule / surgery. Thyroidectomy

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19833337.001).
  • [ISSN] 0021-7697
  • [Journal-full-title] Journal de chirurgie
  • [ISO-abbreviation] J Chir (Paris)
  • [Language] fre
  • [Publication-type] Letter
  • [Publication-country] France
  •  go-up   go-down






Advertisement